var title_f6_37_6736="Pylorus preserving Whipple";
var content_f6_37_6736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pylorus preserving Whipple",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &copy; 2003 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6736=[""].join("\n");
var outline_f6_37_6736=null;
var title_f6_37_6737="Microhematocrit determination";
var content_f6_37_6737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Microhematocrit determination",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The capillary tube is plugged at one end and centrifuged (left). The proportion of blood volume occupied by red cells can be readily determined by eye in a microhematocrit reader (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nathaniel Duke.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6737=[""].join("\n");
var outline_f6_37_6737=null;
var title_f6_37_6738="Aphthoid ulcers Crohns BE";
var content_f6_37_6738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52610%7EGAST%2F75400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52610%7EGAST%2F75400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthoid ulcers in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema demonstrates small aphthoid ulcers in a patient with early Crohn's disease of the colon (arrows). Barium has collected in the superficial erosions, which are surrounded by edematous mucosa. These small erosions, less typically seen in ulcerative colitis, are the precursors of larger discrete ulcers, fistulae, and sinus tracts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic Crohn's colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema demonstrates sacculations along the medial border of the ascending colon (arrows) produced by scarring and fibrosis in a patient with Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6738=[""].join("\n");
var outline_f6_37_6738=null;
var title_f6_37_6739="Biliary transport proteins";
var content_f6_37_6739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Hepatocellular and biliary epithelial transport proteins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conjugated bilirubin and certain other organic anions (OA-) are actively transported from the hepatocyte into the bile canaliculus by the multidrug resistance related protein, MRP 2 (cMOAT). The Na+/K+-ATPase and the K+ channel together maintain a negative intracellular potential of -35mV that contributes to the transport of bilirubin glucuronide into the bile channel. The sodium-taurocholate cotransporter (NTCP) mediates the cotransport of conjugated bile salts (BS-) and sodium (Na+) from portal blood. Organic anion transport polypeptide (OATP) undertakes sodium- independent transport of bile salts (BS-) and other organic anions (OA-) from the portal blood into the hepatocyte. The sister of P-glycoprotein (SPGP) actively transports bile salts (BS-) into the bile. The large scale transport of bile salts by this protein is the main stimulus for bile flow. The multidrug resistance-3-P-glycoprotein (MDR 3) is responsible for the ATP-dependent translocation of phosphatidylcholine (PL) from the inner to the outer leaflet of the membrane bilayer. Multidrug resistance-1-P- glycoprotein (MDR 1) actively transports organic cations (OC+), xenobiotics, and cytotoxins into the bile. FIC1 transports aminophospholipid from the outer to the inner leaflet of the membrane bilayer of the bile canaliculus. Mutations in the gene for this protein has been found in patients with PFIC I and BRIC. AE2 = Chloride-bicarbonate anion exchanger isoform 2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6739=[""].join("\n");
var outline_f6_37_6739=null;
var title_f6_37_6740="Bladder endometriosis resection";
var content_f6_37_6740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Bladder endometriosis: Resection of nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Laparoscopic excision of the endometriotic nodule. The bladder catheter is visible inside the bladder.",
"    <br>",
"     (B) Laparoscopic closure of the bladder.",
"     <br>",
"      (C) Laparoscopic vies at the end of the procedure.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6740=[""].join("\n");
var outline_f6_37_6740=null;
var title_f6_37_6741="Fluoride: Patient drug information";
var content_f6_37_6741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluoride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4632?source=see_link\">",
"     see \"Fluoride: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/59/34742?source=see_link\">",
"     see \"Fluoride: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Act&reg; Kids [OTC];",
"     </li>",
"     <li>",
"      Act&reg; Restoring&trade; [OTC];",
"     </li>",
"     <li>",
"      Act&reg; Total Care&trade; [OTC];",
"     </li>",
"     <li>",
"      Act&reg; [OTC];",
"     </li>",
"     <li>",
"      CaviRinse&trade;;",
"     </li>",
"     <li>",
"      Clinpro&trade; 5000;",
"     </li>",
"     <li>",
"      ControlRx&trade;;",
"     </li>",
"     <li>",
"      ControlRx&trade; Multi;",
"     </li>",
"     <li>",
"      Denta 5000 Plus&trade;;",
"     </li>",
"     <li>",
"      DentaGel&trade;;",
"     </li>",
"     <li>",
"      Epiflur&trade;;",
"     </li>",
"     <li>",
"      Fluor-A-Day&reg;;",
"     </li>",
"     <li>",
"      Fluorabon&trade;;",
"     </li>",
"     <li>",
"      Fluorinse&reg;;",
"     </li>",
"     <li>",
"      Fluoritab;",
"     </li>",
"     <li>",
"      Flura-Drops&reg;;",
"     </li>",
"     <li>",
"      Gel-Kam&reg; Rinse;",
"     </li>",
"     <li>",
"      Gel-Kam&reg; [OTC];",
"     </li>",
"     <li>",
"      Just For Kids&trade; [OTC];",
"     </li>",
"     <li>",
"      Lozi-Flur&trade;;",
"     </li>",
"     <li>",
"      NeutraCare&reg;;",
"     </li>",
"     <li>",
"      NeutraGard&reg; Advanced;",
"     </li>",
"     <li>",
"      Omni Gel&trade; [OTC];",
"     </li>",
"     <li>",
"      OrthoWash&trade;;",
"     </li>",
"     <li>",
"      PerioMed&trade;;",
"     </li>",
"     <li>",
"      Phos-Flur&reg;;",
"     </li>",
"     <li>",
"      Phos-Flur&reg; Rinse [OTC];",
"     </li>",
"     <li>",
"      PreviDent&reg;;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Booster;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Dry Mouth;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Plus&reg;;",
"     </li>",
"     <li>",
"      PreviDent&reg; 5000 Sensitive;",
"     </li>",
"     <li>",
"      StanGard&reg; Perio;",
"     </li>",
"     <li>",
"      Stop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fluor-A-Day",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This supplement is used to stop cavities.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702140",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluoride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the fluoride in your drinking water is greater than or equal to 0.7 parts per million.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take oral drug with milk, other dairy products, calcium, magnesium, or iron.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drink coffee or eat for at least 30 minutes after using the rinse or gel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tooth staining.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2802662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lozenge, drops:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Melt the tablets in the mouth, chew them, swallow them whole, or add them to water or fruit juice. Add to water for use in infant formulas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given. Take alone or mix with liquids or food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Chewable tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694594",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew or crush well. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be mixed with water or fruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug before bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Rinse, gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug before bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Brush with this drug for 2 minutes and then spit out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using the rinse, swish around for 1 minute before spitting out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some products are used every day while others are used 1 time week. Follow what you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12482 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6741=[""].join("\n");
var outline_f6_37_6741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172452\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172453\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011768\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011767\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011772\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011773\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011775\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011770\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011771\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011776\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011777\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4632?source=related_link\">",
"      Fluoride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/59/34742?source=related_link\">",
"      Fluoride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_37_6742="Acalculous cholecystitis";
var content_f6_37_6742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acalculous cholecystitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6742/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/37/6742/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acalculous cholecystitis is an acute necroinflammatory disease of the gallbladder with a multifactorial pathogenesis. It accounts for approximately 10 percent of all cases of acute cholecystitis and is associated with a high morbidity and mortality.",
"   </p>",
"   <p>",
"    The pathophysiology, diagnosis, and treatment of acalculous cholecystitis will be reviewed here. Clinical issues related to acute calculous cholecystitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acalculous cholecystitis is strongly associated with a variety of clinical conditions (",
"    <a class=\"graphic graphic_table graphicRef82539 \" href=\"UTD.htm?2/14/2284\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The clinical presentation is variable, and often depends upon the underlying predisposing conditions. In the critically ill, who may be intubated and sedated, the appearance of unexplained fever, leukocytosis, or vague abdominal discomfort may be the only clue, and warrants a high suspicion for the disease. The insidious presentation in such cases is associated with a high incidence of gallbladder gangrene and perforation. The complications may be manifested by sepsis, shock, and peritonitis.",
"   </p>",
"   <p>",
"    The disease can also occur in outpatients or in the critically ill who are able to provide a more detailed history [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/8\">",
"     8",
"    </a>",
"    ]. In such cases, the presentation may be similar to that seen in calculous cholecystitis, with severe right upper quadrant pain radiating to the right side with associated fever, tenderness, and a positive Murphy's sign (pain elicited during inspiration while palpating the right upper quadrant) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of cases occurring in outpatients is not well-defined. In one of the largest single center reports describing this distinction, 36 of 47 patients (77 percent) identified over a seven year period developed symptoms at home without evidence of acute illness or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/10\">",
"     10",
"    </a>",
"    ]. Significant vascular disease was observed in 72 percent of these patients. Although this suggests that the relative incidence in outpatients may be much higher than is generally recognized, some of these patients may have been mislabeled as having acalculous cholecystitis since it is possible that gallstones or microcrystals had not been appreciated.",
"   </p>",
"   <p>",
"    Physical examination may reveal a palpable right upper quadrant mass and, in up to 20 percent of patients, jaundice secondary to partial biliary obstruction induced by inflammation extending into the common bile duct (CBD). These findings are in sharp contrast to calculous cholecystitis in which jaundice and an abdominal mass are uncommon. Acalculous cholecystitis should be considered in the differential diagnosis of patients who develop postoperative jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory tests are nonspecific. Leukocytosis with a left shift is seen in 70 to 85 percent of patients. Abnormal liver function tests are much more common in acalculous than calculous cholecystitis and include hyperbilirubinemia, a mild increase in serum alkaline phosphatase, and serum aminotransferases in the absence of true cholangitis due to an obstructing CBD stone. A serum amylase is helpful and blood cultures should be taken prior to antibiotic therapy.",
"   </p>",
"   <p>",
"    Patients with a smoldering presentation characterized by recurrent biliary symptoms for months or years have also been described. While this has been sometimes labeled as \"chronic acalculous cholecystitis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], the degree to which gallstones or microcrystals have been sought is variable, and the relationship of gallbladder dysfunction (sometimes used to implicate this disorder) to symptoms is not always clear. Thus, these patients may in fact have gallstone-related disease or other causes of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"     \"Uncomplicated gallstone disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is the investigation of first choice and strongly recommended whenever acalculous cholecystitis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/9,14-16\">",
"     9,14-16",
"    </a>",
"    ]. Additional radiologic studies should include plain abdominal X-ray, which is useful predominantly to exclude a perforated viscus, bowel ischemia, or renal stones. An advantage of ultrasonography includes its ability to examine the liver, pancreas, kidneys, and bile ducts in addition to the gallbladder.",
"   </p>",
"   <p>",
"    Ultrasonographic features suggestive of acalculous cholecystitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of gallstones or sludge",
"     </li>",
"     <li>",
"      Thickening of the gallbladder wall (&gt;5 mm) with pericholecystic fluid",
"     </li>",
"     <li>",
"      A positive Murphy's sign induced by the ultrasound probe",
"     </li>",
"     <li>",
"      Failure to visualize the gallbladder",
"     </li>",
"     <li>",
"      Emphysematous cholecystitis with gas bubbles arising in the fundus of the gallbladder (champagne sign)",
"     </li>",
"     <li>",
"      Frank perforation of the gallbladder with associated abscess formation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In stable patients in whom the diagnosis is unclear after ultrasonography, radioisotope HIDA scan may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/17\">",
"     17",
"    </a>",
"    ]. HIDA is an iminodiacetic acid derivative, which is given by intravenous injection, taken up by hepatocytes, and excreted into bile with concentration in the gallbladder. Failure to opacify the gallbladder is the most sensitive and specific finding. Leakage into the pericholecystic space suggests perforation. HIDA is not recommended in critically ill patients in whom a delay in therapy can be potentially fatal (",
"    <a class=\"graphic graphic_algorithm graphicRef50032 \" href=\"UTD.htm?30/12/30912\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    False positive results in which the gallbladder does not visualize in spite of a non-obstructed cystic duct can occur in a variety of settings including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe liver disease, which may lead to abnormal uptake and excretion of the tracer.",
"     </li>",
"     <li>",
"      Fasting patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      , in whom the gallbladder is already maximally full due to prolonged lack of stimulation.",
"     </li>",
"     <li>",
"      Biliary sphincterotomy, which may result in low resistance for bile flow, leading to preferential excretion of the tracer into the duodenum without filling of the gallbladder.",
"     </li>",
"     <li>",
"      Hyperbilirubinemia, which may be associated with impaired hepatic clearance of iminodiacetic acid compounds. Newer agents commonly used in cholescintigraphy (diisopropyl and m-bromothymethyl iminodiacetic acid) have generally overcome this limitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for acalculous cholecystitis includes calculous cholecystitis, peptic ulceration with or without perforation, acute pancreatitis, right-sided pyelonephritis, and hepatic or subphrenic abscess. Many of these conditions can be ruled out by clinical examination, laboratory tests, and plain abdominal X-ray or CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conditions associated with acalculous cholecystitis lead to gallbladder stasis and ischemia, which result in a local inflammatory response in the gallbladder wall. Pathologically, there is endothelial injury, gallbladder ischemia, and stasis, which result in the concentration of bile salts, gallbladder distension, and eventually necrosis of the gallbladder tissue. Perforation occurs in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple risk factors are present in the majority of patients with acalculous cholecystitis (",
"    <a class=\"graphic graphic_table graphicRef82539 \" href=\"UTD.htm?2/14/2284\">",
"     table 1",
"    </a>",
"    ). In some cases, specific infections are responsible and should be managed appropriately (",
"    <a class=\"graphic graphic_table graphicRef56077 \" href=\"UTD.htm?26/11/26811\">",
"     table 2",
"    </a>",
"    ). As an example, acalculous cholecystitis occurring in HIV-infected and other immunosuppressed patients may be due to opportunistic infections such as microsporidia, Cryptosporidium, or cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/20\">",
"     20",
"    </a>",
"    ]. More often, however, these infections cause a cholangiopathy without cholecystitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=see_link\">",
"     \"AIDS cholangiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management should be instituted promptly, especially in critically ill patients. After blood cultures are obtained, intravenous broad spectrum antibiotics should be started. Once acalculous cholecystitis is established, secondary infection with enteric pathogens, including Escherichia coli, Enterococcus faecalis, Klebsiella, Pseudomonas, Proteus species, and Bacteroides is common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/16\">",
"     16",
"    </a>",
"    ]. Antibiotic therapy should be directed against these organisms.",
"   </p>",
"   <p>",
"    The choice of antibiotics should take into consideration recent use of antibiotics. Patients who were previously on broad-spectrum antibiotics can be treated with a third generation cephalosporin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     imipenem/cilastatin",
"    </span>",
"    plus or minus antifungal therapy (usually with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) depending upon the duration and intensity of prior broad spectrum antibiotic therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    can be added when the incidence of nosocomial infection with MRSA is known or suspected to be likely.",
"   </p>",
"   <p>",
"    Those who have not previously received antibiotics can receive empiric therapy with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"      piperacillin",
"     </a>",
"     /tazobactam,",
"    </span>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam,",
"    </span>",
"    or imipenem. Aminoglycosides should be avoided when possible in the elderly or those with renal insufficiency, although one or two doses can be given empirically pending microbiological results in most patients without serious risk.",
"   </p>",
"   <p>",
"    The definitive therapy is cholecystectomy with drainage of any associated abscess. Both open and laparoscopic cholecystectomy have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/3,9,12,21,22\">",
"     3,9,12,21,22",
"    </a>",
"    ]. The gallbladder is often encased in an inflammatory mass, which makes the laparoscopic approach more complicated because of a higher risk of bile ductular and vascular injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .) However, the laparoscopic approach may still be preferred in critically ill patients. It is appropriate for the experienced surgeon to attempt a laparoscopic approach but convert to an open cholecystectomy if necessary.",
"   </p>",
"   <p>",
"    In some unstable, desperately ill patients, any form of surgical intervention may be contraindicated. In these patients, drainage of the gallbladder may be performed under radiologic guidance via a percutaneous cholecystostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. In one study, for example, 82 patients in the intensive care unit who had persistent unexplained sepsis and sonographic abnormalities consistent with biliary disease underwent percutaneous cholecystostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/23\">",
"     23",
"    </a>",
"    ]. An improvement in clinical condition was observed in 59 percent within 48 hours. The sonographic findings were not predictive of the response to cholecystostomy. There were no complications associated with catheter insertion. However, in other reports, complications associated with percutaneous cholecystostomy included hepatic bleeding, dislodgement of the catheter, and mortality related to peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the gallbladder wall is necrotic or perforated, percutaneous cholecystostomy is inappropriate. Emphysematous cholecystitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56763 \" href=\"UTD.htm?41/57/42899\">",
"     image 1",
"    </a>",
"    ) is an obvious contraindication; however, it may not be possible to determine this prior to drainage in patients who do not have gas within the gallbladder wall or extravasation of contrast on HIDA scan. Patients who fail to improve or worsen following drainage should be taken for cholecystectomy.",
"   </p>",
"   <p>",
"    In many instances, percutaneous cholecystostomy is more than a temporizing measure. Subsequent cholecystectomy is often unnecessary if the patient recovers and the underlying problem causing the cholecystitis is no longer present [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Isolated cases of successful transpapillary endoscopic drainage of the gallbladder have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality in patients with acalculous cholecystitis depends upon coexistent medical or surgical conditions but can be as high as 90 percent in critically ill patients and as low as 10 percent in community-acquired cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/9,32\">",
"     9,32",
"    </a>",
"    ]. Mortality is also affected by the rapidity of diagnosis. Gallbladder necrosis, gangrene, and perforation are frequently present at the time of diagnosis, particularly in the critically ill [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Complications were more likely in older patients (mean age 61 versus 54) with a high white blood cell count in one review of 52 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6742/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acalculous cholecystitis is an acute necroinflammatory disease of the gallbladder with a multifactorial pathogenesis. It accounts for approximately 10 percent of all cases of acute cholecystitis and is associated with a high morbidity and mortality. Acalculous cholecystitis is strongly associated with a variety of clinical conditions (",
"      <a class=\"graphic graphic_table graphicRef82539 \" href=\"UTD.htm?2/14/2284\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the critically ill, who may be intubated and sedated, the appearance of unexplained fever, leukocytosis, or vague abdominal discomfort may be the only clue to the presence of acalculous cholecystitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acalculous cholecystitis can also occur in outpatients or in patients who are critically ill but are able to provide a more detailed history. In such cases, the presentation may be similar to that seen in calculous cholecystitis, with severe right upper quadrant pain radiating to the right side with associated fever, tenderness, and a positive Murphy's sign (pain elicited during inspiration while palpating the right upper quadrant). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonography is the investigation of first choice for acalculous cholecystitis, although additional testing may be required. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management should be instituted promptly, especially in the critically ill. After blood cultures are obtained, intravenous broad spectrum antibiotics should be started. Once acalculous cholecystitis is established, secondary infection with enteric pathogens, including Escherichia coli, Enterococcus faecalis, Klebsiella, Pseudomonas, Proteus species, and Bacteroides is common. Antibiotic therapy should be directed against these bacteria. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive therapy is cholecystectomy with drainage of any associated abscess. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some unstable, desperately ill patients, any form of surgical intervention may be contraindicated. In these patients, drainage of the gallbladder may be performed under radiologic guidance via a percutaneous cholecystostomy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality depends upon coexistent medical or surgical conditions, but can be as high as 90 percent in critically ill patients and as low as 10 percent in community-acquired cases. Mortality is also affected by the rapidity of diagnosis. Gallbladder necrosis, gangrene, and perforation are frequently present at the time of diagnosis, particularly in the critically ill. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/1\">",
"      Shapiro MJ, Luchtefeld WB, Kurzweil S, et al. Acute acalculous cholecystitis in the critically ill. Am Surg 1994; 60:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/2\">",
"      Gofrit O, Eid A, Pikarsky A, et al. Cholesterol embolisation causing chronic acalculous cholecystitis. Eur J Surg 1996; 162:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/3\">",
"      Schwesinger WH, Diehl AK. Changing indications for laparoscopic cholecystectomy. Stones without symptoms and symptoms without stones. Surg Clin North Am 1996; 76:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/4\">",
"      Wiboltt KS, Jeffrey RB Jr. Acalculous cholecystitis in patients undergoing bone marrow transplantation. Eur J Surg 1997; 163:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/5\">",
"      Romero Ganuza FJ, La Banda G, Montalvo R, Mazaira J. Acute acalculous cholecystitis in patients with acute traumatic spinal cord injury. Spinal Cord 1997; 35:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/6\">",
"      Nash JA, Cohen SA. Gallbladder and biliary tract disease in AIDS. Gastroenterol Clin North Am 1997; 26:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/7\">",
"      McChesney JA, Northup PG, Bickston SJ. Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: a case series and review of pathophysiology. Dig Dis Sci 2003; 48:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/8\">",
"      Ryu JK, Ryu KH, Kim KH. Clinical features of acute acalculous cholecystitis. J Clin Gastroenterol 2003; 36:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/9\">",
"      Kalliafas S, Ziegler DW, Flancbaum L, Choban PS. Acute acalculous cholecystitis: incidence, risk factors, diagnosis, and outcome. Am Surg 1998; 64:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/10\">",
"      Savoca PE, Longo WE, Zucker KA, et al. The increasing prevalence of acalculous cholecystitis in outpatients. Results of a 7-year study. Ann Surg 1990; 211:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/11\">",
"      Faust TW, Reddy KR. Postoperative jaundice. Clin Liver Dis 2004; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/12\">",
"      Adams DB, Tarnasky PR, Hawes RH, et al. Outcome after laparoscopic cholecystectomy for chronic acalculous cholecystitis. Am Surg 1998; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/13\">",
"      Jagannath SB, Singh VK, Cruz-Correa M, et al. A long-term cohort study of outcome after cholecystectomy for chronic acalculous cholecystitis. Am J Surg 2003; 185:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/14\">",
"      Lam&eacute;ris JS, van Overhagen H. Imaging and intervention in patients with acute right upper quadrant disease. Baillieres Clin Gastroenterol 1995; 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/15\">",
"      Molenat F, Boussuges A, Valantin V, Sainty JM. Gallbladder abnormalities in medical ICU patients: an ultrasonographic study. Intensive Care Med 1996; 22:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/16\">",
"      Wang AJ, Wang TE, Lin CC, et al. Clinical predictors of severe gallbladder complications in acute acalculous cholecystitis. World J Gastroenterol 2003; 9:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/17\">",
"      Westlake PJ, Hershfield NB, Kelly JK, et al. Chronic right upper quadrant pain without gallstones: does HIDA scan predict outcome after cholecystectomy? Am J Gastroenterol 1990; 85:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/18\">",
"      Venkataramani A, Strong RM, Anderson DS, et al. Abnormal duodenal bile composition in patients with acalculous chronic cholecystitis. Am J Gastroenterol 1998; 93:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/19\">",
"      Janowitz P, Kratzer W, Zemmler T, et al. Gallbladder sludge: spontaneous course and incidence of complications in patients without stones. Hepatology 1994; 20:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/20\">",
"      Wind P, Chevallier JM, Jones D, et al. Cholecystectomy for cholecystitis in patients with acquired immune deficiency syndrome. Am J Surg 1994; 168:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/21\">",
"      Frassinelli P, Werner M, Reed JF 3rd, Scagliotti C. Laparoscopic cholecystectomy alleviates pain in patients with acalculous biliary disease. Surg Laparosc Endosc 1998; 8:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/22\">",
"      Yang HK, Hodgson WJ. Laparoscopic cholecystostomy for acute acalculous cholecystitis. Surg Endosc 1996; 10:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/23\">",
"      Boland GW, Lee MJ, Leung J, Mueller PR. Percutaneous cholecystostomy in critically ill patients: early response and final outcome in 82 patients. AJR Am J Roentgenol 1994; 163:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/24\">",
"      McLoughlin RF, Patterson EJ, Mathieson JR, et al. Radiologically guided percutaneous cholecystostomy for acute cholecystitis: long-term outcome in 50 patients. Can Assoc Radiol J 1994; 45:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/25\">",
"      Sugiyama M, Tokuhara M, Atomi Y. Is percutaneous cholecystostomy the optimal treatment for acute cholecystitis in the very elderly? World J Surg 1998; 22:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/26\">",
"      vanSonnenberg E, D'Agostino HB, Goodacre BW, et al. Percutaneous gallbladder puncture and cholecystostomy: results, complications, and caveats for safety. Radiology 1992; 183:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/27\">",
"      England RE, McDermott VG, Smith TP, et al. Percutaneous cholecystostomy: who responds? AJR Am J Roentgenol 1997; 168:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/28\">",
"      Davis CA, Landercasper J, Gundersen LH, Lambert PJ. Effective use of percutaneous cholecystostomy in high-risk surgical patients: techniques, tube management, and results. Arch Surg 1999; 134:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/29\">",
"      Spira RM, Nissan A, Zamir O, et al. Percutaneous transhepatic cholecystostomy and delayed laparoscopic cholecystectomy in critically ill patients with acute calculus cholecystitis. Am J Surg 2002; 183:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/30\">",
"      Hadas-Halpern I, Patlas M, Knizhnik M, et al. Percutaneous cholecystostomy in the management of acute cholecystitis. Isr Med Assoc J 2003; 5:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/31\">",
"      Huibregtse K, van Amerongen R, van Deventer SJ. Drainage of the gallbladder in patients with acute acalculous cholecystitis by transpapillary endoscopic cholecystoxeransis. Gastrointest Endosc 1994; 40:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6742/abstract/32\">",
"      Barie PS, Eachempati SR. Acute acalculous cholecystitis. Curr Gastroenterol Rep 2003; 5:302.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 672 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6742=[""].join("\n");
var outline_f6_37_6742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/672|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/12/30912\" title=\"algorithm 1\">",
"      Diagnosis acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/672|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/57/42899\" title=\"diagnostic image 1\">",
"      Emphysematous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/14/2284\" title=\"table 1\">",
"      Risk acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/11/26811\" title=\"table 2\">",
"      Infxn acalculous cholecystitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26069?source=related_link\">",
"      AIDS cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_37_6743="Diagnosis and antiviral therapy of human herpesvirus 8 infection";
var content_f6_37_6743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and antiviral therapy of human herpesvirus 8 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6743/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6743/contributors\">",
"     Corey Casper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6743/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6743/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/37/6743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first disease associated with human herpesvirus 8 (HHV-8) infection was Kaposi sarcoma (KS). Subsequently, several other conditions, such as primary effusion lymphoma (PEL, also known as body cavity based lymphoma) and Castleman's disease (CD), were also linked to this virus. A severe inflammatory syndrome attributed to interleukin-6 production has also been described among HHV-8 infected individuals and is known as the Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICKS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/1\">",
"     1",
"    </a>",
"    ]. Host factors and other related issues influence disease expression, since HHV-8 infection is relatively common. The onset of disease typically occurs several years after acquisition of infection. HHV-8 can also induce a primary infection characterized by fever and a maculopapular rash in children and more marked manifestations in immunocompromised individuals.",
"   </p>",
"   <p>",
"    The diagnosis of HHV-8 infection and the possible role of antiviral therapy will be reviewed here. The epidemiology, mode of transmission, and disease associations of HHV-8 infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link\">",
"     \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of diagnostic testing for human herpesvirus 8 (HHV-8) has been hampered by the lack of a cell line that can serve as a culture system for isolating the virus from tissue or mucosal sites. The identification of HHV-8 positive immortalized lymphoma cell lines (eg, BCBL-1, KS-1) has been an important step in maintaining virus for study and in the development of serologic testing. These cell lines contain latent virus in an episomal form that can be stimulated by phorbol esters or butyrate into active replication with production of intact virions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different polymerase chain reaction (PCR) assays employing primers unique for HHV-8 have been described. HHV-8 DNA can be identified using PCR in virtually all biopsies of Kaposi sarcoma (KS), including AIDS-associated KS, classic KS, and endemic KS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/3-9\">",
"     3-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR techniques for investigation of disease associations and molecular epidemiology have proven to be of enormous value, but the following caveats must be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most PCR-based methods have used DNA-based assays, which detects both latent and lytically replicating virus. Differentiation between these two forms of viral infection may have both diagnostic as well as therapeutic importance regarding the potential benefit of antiviral therapy.",
"     </li>",
"     <li>",
"      Because HHV-8 is often present sporadically in tissue, low copy numbers are frequent.",
"     </li>",
"     <li>",
"      Laboratory contamination can arise with PCR leading to false positive results; conditions with low copy numbers make this possibility more likely. Sequence variability between isolates can help to define this issue more completely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical applications of PCR for HHV-8 disease are limited. The detection of HHV-8 DNA in the peripheral blood can support a diagnosis of KS. The prevalence of viremia in persons asymptomatically infected with HHV-8 ranges from 4 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Among persons with HIV infection, the detection of HHV-8 in the peripheral blood is associated with an increased risk for development of KS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/11\">",
"     11",
"    </a>",
"    ]. Even among persons with KS, however, viremia is not universal, limiting the utility of PCR for the diagnosis of KS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In sub-Saharan Africa, where the detection of HHV-8 in the peripheral blood is more common among individuals with KS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/13\">",
"     13",
"    </a>",
"    ], the quantity of HHV-8 DNA in the plasma was useful in both predicting survival and response to treatment after a diagnosis of KS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to KS, asymptomatic individuals with HHV-8 associated multicentric Castleman disease (MCD) are universally viremic with active disease flares [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/15\">",
"     15",
"    </a>",
"    ]. HHV-8 quantification in plasma or peripheral blood mononuclear cells by PCR may be a useful means for diagnosing an active flare of MCD or following response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/16\">",
"     16",
"    </a>",
"    ]. Since patients with MCD also have higher quantities of HHV-8 DNA detected in the blood, it has been suggested that the detection of more than 10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    of HHV-8 DNA in the peripheral blood be used as a sensitive and specific discriminator between patients likely to have MCD versus KS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H10#H10\">",
"     \"Castleman's disease\", section on 'Multicentric Castleman's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of serologic assays have been used to measure antibodies to HHV-8. These assays are moderately sensitive and specific for the detection of previous infection with HHV-8, but are of limited clinical utility. The indirect immunofluorescence assay (IFA) which measures inhibition of fluorescence against HHV-8 infected cells has been used the most extensively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/18\">",
"     18",
"    </a>",
"    ]. Approximately 85 percent of persons with KS from whom HHV-8 DNA has been detected in lesions have antibodies to HHV-8 by IFA, and these antibodies are usually of high titer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the production of recombinant proteins to the virus, additional serologic assays have been developed. One difficulty with serologic tests in general is that serology only indicates past exposure to an agent. Because only a small portion of HHV-8 infected individuals are thought to develop clinical disease, such as KS, a positive serologic test in an asymptomatic individual could represent subclinical infection or a false positive result due to nonspecific serologic cross reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Immunofluorescence assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the IFA assay, serum is reacted against HHV-8 immortalized lymphoma cell lines; bound human antibody against viral antigens is visualized with fluorescent labeled antihuman IgG antibodies. The assay can be used to detect antibodies against latent phase viral antigens that will produce a characteristic nuclear pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/19\">",
"     19",
"    </a>",
"    ]. Alternatively, the virus can be stimulated with phorbol esters to produce full lytic antigens that will allow testing for lytic phase antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with KS have antibodies to both latent and lytic phage antigens. In comparative studies between laboratories, relatively good consistency has been achieved with IFA measuring antibodies against latent antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the results of assays directed at lytic antigens are more variable and have given rise to controversy about the true prevalence of HHV-8 infection in different populations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Western blot",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of Western blot assays have been developed using recombinant proteins produced from the HHV-8 genome. Latent antigens that have been used include a protein produced from a part of the genome identified as open reading frame (ORF) 73, which is named latency associated nuclear antigen (LANA) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Recombinant lytic antigens have also been produced and used in Western blot assays. These proteins have included ORF 65 (a capsid related protein), K 8.1, and ORF 26 (minor capsid protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/19,25-27\">",
"     19,25-27",
"    </a>",
"    ]. Although it might be assumed that the Western blot assays have better specificity than IFAs, the testing characteristics for these assays have not been systematically established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Enzyme immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both whole virus lysate and recombinant proteins have been used for enzyme linked immunosorbent assays (ELISA) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/20,28-30\">",
"     20,28-30",
"    </a>",
"    ]. The optimal serologic assay technique cannot be determined at present. A study comparing seven different immunofluorescence and ELISA assays found that, while the sensitivity for detecting HHV-8 antibodies was fairly good in patients with KS (67 to 100 percent), there was significant discordance among the various methods in low risk populations (eg, blood donors) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/20\">",
"     20",
"    </a>",
"    ]. This variability between different testing modalities makes it difficult to know which test is most accurate for seroprevalence studies in the general population. It has been suggested that a combination of whole virion ELISA and lytic IFA may be the most sensitive method for diagnosing HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/20,30-32\">",
"     20,30-32",
"    </a>",
"    ]. Hopefully, with refinements in serologic testing over the next several years, making the correct diagnosis of HHV-8 infection should grow easier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H166125681\">",
"    <span class=\"h3\">",
"     Luciferase immunoprecipitation assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the suboptimal test characteristics of single-antigen immunologic assays, technology has been developed to simultaneously survey antibodies to multiple HHV-8 antigens. In one study, luciferase immunoprecipitation assays targeting a combination of latent and lytic antigens helped differentiate patients with KS from those with MCD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/33\">",
"     33",
"    </a>",
"    ]. However, there was significant overlap in assay results between persons with HHV-8-associated disease and persons selected as healthy controls, calling into question whether this technology could accurately differentiate persons with and without HHV-8 infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various modalities have been used to prevent and treat human herpesvirus 8 (HHV-8)-related diseases. Current strategies include targeting HHV-8 replication, reconstituting the immune system in immunosuppressed patients, and chemotherapy aimed at transformed cells in HHV-8 associated malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of antiviral agents on HHV-8 replication has not been extensively studied. There are several reports of in vitro testing of herpesvirus DNA polymerase inhibitors against HHV-8. These agents would presumably be effective against the lytic phase of the virus but would probably have less activity in the latent phase in host or tumor tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     In vitro activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of different agents can be compared by testing the ability to block stimulation of lytic replication in HHV-8-infected cell lines (eg, BCBL-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , and lobucavir all have some in vitro activity in this type of testing system. By contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    does not appear to have high levels of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/39\">",
"     39",
"    </a>",
"    ]. The HIV protease inhibitor (PI)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    was shown to have an inhibitory effect on HHV-8 replication in vitro, which was similar to that seen with ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/40\">",
"     40",
"    </a>",
"    ]. Nelfinavir has previously been shown to inhibit the growth of Kaposi sarcoma (KS) tumors in vitro",
"    <sup>",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/41\">",
"     41",
"    </a>",
"    ]. The inhibition of HHV-8 replication in vitro was notably restricted to nelfinavir when a broad panel of PIs was tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     In vivo activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo data are limited. A double-blind, placebo-controlled, crossover trial assessed the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (900 mg once daily) versus placebo in 26 men infected with HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/42\">",
"     42",
"    </a>",
"    ]. Valganciclovir use was associated with significantly less oropharyngeal shedding of HHV-8 as detected by daily quantitative polymerase chain reaction (PCR) assays (23 versus 44 percent with placebo).",
"   </p>",
"   <p>",
"    In contrast, a report of seven HIV-infected individuals receiving intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    for CMV retinitis found no difference in pre- and post-treatment HHV-8 DNA levels in peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of HIV-1 seropositive men in Seattle and Peru showed that both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    use was associated with modest but significant reductions in the frequency of HHV-8 detection in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6743/abstract/44\">",
"     44",
"    </a>",
"    ]. The clinical significance of these findings remains to be determined. The use of antiretroviral therapy (ART), however, was associated with a nearly 90 percent reduction in the frequency of HHV-8 detected at the oropharynx, and could help explain why KS incidence has decreased so dramatically in resource-rich settings where ART has been widely used.",
"   </p>",
"   <p>",
"    Possible therapies for AIDS-related Kaposi sarcoma and two other HHV-8 related diseases, primary effusion lymphoma and Castleman's disease, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link\">",
"     \"Castleman's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1719306338\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first disease associated with human herpesvirus 8 (HHV-8) infection was Kaposi sarcoma (KS). Subsequently, several other conditions, such as primary effusion lymphoma (PEL, also known as body cavity based lymphoma), Castleman's disease (CD), and Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICKS) were also linked to this virus. The onset of disease typically occurs several years after acquisition of infection. HHV-8 primary infection may be characterized by fever and a maculopapular rash in children and more marked manifestations in immunocompromised individuals. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HHV-8 DNA can be identified using polymerase chain reaction (PCR) assays in virtually all biopsies of KS, including AIDS-associated KS, classic KS, and endemic KS. Among persons with HIV infection, the detection of HHV-8 in the peripheral blood is associated with an increased risk for development of KS. Even among persons with KS, however, viremia is not universal, limiting the utility of PCR for the diagnosis of KS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Polymerase chain reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to KS, asymptomatic individuals with HHV-8 associated multicentric Castleman disease (MCD) are universally viremic with active disease flares. The quantity of HHV-8 detected may both allow for differentiation between KS and MCD and help predict survival in patients with KS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Polymerase chain reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several types of serologic assays have been used to measure antibodies to HHV-8. These assays are moderately sensitive and specific for the detection of previous infection with HHV-8, but are of limited clinical utility. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various modalities have been used to prevent and treat HHV-8-related diseases. Current strategies include targeting HHV-8 replication, reconstituting the immune system in immunocompromised patients, and chemotherapy aimed at transformed cells in HHV-8 associated malignancies.(See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      , lobucavir, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      all have some in vitro activity against HHV-8. By contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      does not appear to have high levels of in vitro anti-HHV8 activity. Studies in HIV-positive men support the ability of ganciclovir,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      , and antiretroviral therapy to suppress HHV-8 replication. Possible therapies for AIDS-related Kaposi sarcoma and two other HHV-8 related diseases, primary effusion lymphoma and Castleman's disease, are discussed separately. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antiviral therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"       \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link\">",
"       \"Castleman's disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/1\">",
"      Uldrick TS, Wang V, O'Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 2010; 51:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/2\">",
"      Cesarman E, Moore PS, Rao PH, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 1995; 86:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/3\">",
"      Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/4\">",
"      Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995; 332:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/5\">",
"      Chuck S, Grant RM, Katongole-Mbidde E, et al. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis 1996; 173:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/6\">",
"      Buonaguro FM, Tornesello ML, Beth-Giraldo E, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/7\">",
"      Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med 1999; 340:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/8\">",
"      Purvis SF, Katongole-Mbidde E, Johnson JL, et al. High incidence of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda. J Infect Dis 1997; 175:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/9\">",
"      Dupin N, Grandadam M, Calvez V, et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 1995; 345:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/10\">",
"      Taylor MM, Chohan B, Lavreys L, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis 2004; 190:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/11\">",
"      Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003; 17:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/12\">",
"      Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/13\">",
"      Johnston C, Orem J, Okuku F, et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One 2009; 4:e4222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/14\">",
"      Borok M, Fiorillo S, Gudza I, et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010; 51:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/15\">",
"      Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/16\">",
"      Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/17\">",
"      Sayer R, Paul J, Tuke PW, et al. Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma? Int J STD AIDS 2011; 22:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/18\">",
"      Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/19\">",
"      Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/20\">",
"      Rabkin CS, Schulz TF, Whitby D, et al. Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group. J Infect Dis 1998; 178:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/21\">",
"      Enbom M, Sheldon J, Lennette E, et al. Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study. J Med Virol 2000; 62:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/22\">",
"      Topino S, Vincenzi L, Mezzaroma I, et al. Correlation between enzyme-linked immunosorbent assay and immunofluorescence assay with lytic antigens for detection of antibodies to human herpesvirus 8. Clin Diagn Lab Immunol 2001; 8:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/23\">",
"      Kedes DH, Lagunoff M, Renne R, Ganem D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Invest 1997; 100:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/24\">",
"      Olsen SJ, Sarid R, Chang Y, Moore PS. Evaluation of the latency-associated nuclear antigen (ORF73) of Kaposi's sarcoma-associated herpesvirus by peptide mapping and bacterially expressed recombinant western blot assay. J Infect Dis 2000; 182:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/25\">",
"      Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996; 348:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/26\">",
"      Davis DA, Humphrey RW, Newcomb FM, et al. Detection of serum antibodies to a Kaposi's sarcoma-associated herpesvirus-specific peptide. J Infect Dis 1997; 175:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/27\">",
"      Chandran B, Bloomer C, Chan SR, et al. Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. Virology 1998; 249:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/28\">",
"      Chatlynne LG, Lapps W, Handy M, et al. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immunodeficiency syndrome patients, and Kaposi's sarcoma patients using a whole virus enzyme-linked immunosorbent assay. Blood 1998; 92:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/29\">",
"      Andr&eacute; S, Schatz O, Bogner JR, et al. Detection of antibodies against viral capsid proteins of human herpesvirus 8 in AIDS-associated Kaposi's sarcoma. J Mol Med (Berl) 1997; 75:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/30\">",
"      Casper C, Krantz E, Taylor H, et al. Assessment of a combined testing strategy for detection of antibodies to human herpesvirus 8 (HHV-8) in persons with Kaposi's sarcoma, persons with asymptomatic HHV-8 infection, and persons at low risk for HHV-8 infection. J Clin Microbiol 2002; 40:3822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/31\">",
"      Spira TJ, Lam L, Dollard SC, et al. Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection. J Clin Microbiol 2000; 38:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/32\">",
"      Engels EA, Whitby D, Goebel PB, et al. Identifying human herpesvirus 8 infection: performance characteristics of serologic assays. J Acquir Immune Defic Syndr 2000; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/33\">",
"      Burbelo PD, Issa AT, Ching KH, et al. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. J Infect Dis 2010; 201:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/34\">",
"      Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/35\">",
"      Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997; 11:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/36\">",
"      Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41:2754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/37\">",
"      Flore O, Gao SJ. Effect of DNA synthesis inhibitors on Kaposi's sarcoma-associated herpesvirus cyclin and major capsid protein gene expression. AIDS Res Hum Retroviruses 1997; 13:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/38\">",
"      Cannon JS, Hamzeh F, Moore S, et al. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999; 73:4786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/39\">",
"      Casper C, Wald A. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr Top Microbiol Immunol 2007; 312:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/40\">",
"      Gantt S, Carlsson J, Ikoma M, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 2011; 55:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/41\">",
"      Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/42\">",
"      Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/43\">",
"      Boivin G, Gaudreau A, Toma E, et al. Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Antimicrob Agents Chemother 1999; 43:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6743/abstract/44\">",
"      Cattamanchi A, Saracino M, Selke S, et al. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. J Med Virol 2011; 83:1696.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8319 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6743=[""].join("\n");
var outline_f6_37_6743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1719306338\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Immunofluorescence assay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Western blot",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Enzyme immunoassays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H166125681\">",
"      - Luciferase immunoprecipitation assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - In vitro activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - In vivo activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1719306338\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=related_link\">",
"      Virology, epidemiology, and transmission of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_37_6744="Chapter 8C: Regulation of renal Na+ excretion";
var content_f6_37_6744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 8C: Regulation of renal Na+ excretion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6744/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/37/6744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 23, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal Na+ excretion varies directly with the effective circulating volume. When the effective volume is expanded, the urine Na+ concentration can exceed 100",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    In contrast, the urine can be rendered virtually Na+-free (urine Na+ concentration as low as 1",
"    <span class=\"nowrap\">",
"     meq/L&dagger;)",
"    </span>",
"    in the presence of volume depletion and normal renal function. These homeostatic changes in Na+ excretion can result from alterations both in the filtered load, determined primarily by the GFR, and in tubular reabsorption, which is affected by multiple factors. As will be seen, an abnormality in any one factor does not preclude the maintenance of Na+ balance, a finding indicative of the substantial overlap involved in volume regulation.",
"   </p>",
"   <p>",
"    &dagger; How Na+ can enter the cell to be reabsorbed when its luminal concentration falls below that of the cell is described on page 000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOMERULAR FILTRATION RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GFR tends to increase with volume expansion and to fall with volume depletion, both of which can contribute to the associated changes in Na+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/1\">",
"     1",
"    </a>",
"    ]. However, alterations in the GFR are not required for the maintenance of Na+ balance. As an example, patients with less than end-stage renal disease may have a substantial reduction in GFR. Nevertheless, they are usually able (in the absence of the nephrotic syndrome) to adjust Na+ excretion to match intake by decreasing the rate of tubular reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/2\">",
"     2",
"    </a>",
"    ]. The importance of tubular reabsorption is also illustrated by the phenomenon of glomerulotubular balance in which a primary alteration in GFR leads to a parallel change in tubular reabsorption and, therefore, relatively little variation in urinary Na+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=see_link&amp;anchor=H11#H11\">",
"     \"Chapter 3A: Cell model for proximal transport\", section on 'Glomerulotubular balance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TUBULAR REABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, it is changes in tubular reabsorption that constitute the main adaptive response to fluctuations in the effective circulating volume. How this occurs can be appreciated from the following table (",
"    <a class=\"graphic graphic_table graphicRef62655 \" href=\"UTD.htm?20/3/20539\">",
"     table 1",
"    </a>",
"    ), which depicts the sites and determinants of segmental Na+ reabsorption. Although the loop of Henle and distal tubule make an important overall contribution to net Na+ handling, transport in these segments primarily varies with the amount of Na+ delivered, i.e., reabsorption is flow-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\"",
"    </a>",
"    .) In comparison, the neurohumoral regulation of Na+ reabsorption according to body needs occurs primarily in the proximal and collecting tubules.",
"   </p>",
"   <p>",
"    As an example, mild volume depletion in the rat results in a decrease in Na+ excretion that is mostly due to enhanced collecting tubule reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/5\">",
"     5",
"    </a>",
"    ]; this effect is mediated at least in part by an increase in the secretion of aldosterone. Proximal reabsorption also may be enhanced, especially with greater degrees of hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This response is associated with increased activity of the luminal membrane Na+-H+ exchanger that is responsible for both NaHCO3 and NaCl reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=see_link\">",
"     \"Chapter 3A: Cell model for proximal transport\"",
"    </a>",
"    .) Increased secretion of angiotensin II and norepinephrine probably play an important role in this stimulation of proximal transport [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/7\">",
"     7",
"    </a>",
"    ]. Reabsorption in the loop of Henle may also be increased in this setting, an effect that may be mediated by a reduction in medullary interstitial pressure (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Pressure natriuresis'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes are reversed with volume expansion as collecting tubule and, if necessary, proximal and loop NaCl and water reabsorption all may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Decreased activity of the renin-angiotensin-aldosterone system, and increased secretion of ANP (which can also raise the GFR) may be particularly important in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Day-to-day regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above findings were obtained from experiments in which relatively large changes in volume were induced. In normal humans, however, variations in daily Na+ intake require very small percentage changes in Na+ excretion for balance to be maintained. Suppose, for example, an adult man has a GFR of 160",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    and a plasma water Na+ concentration of 150",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The daily filtered load of Na+ in this setting is 24,000 meq. If intake is normally 120 meq per day, then only 0.5 percent of the filtered load has to be excreted. An increase in intake to 180 meq will require a minimal rise in fractional excretion to only 0.67 percent.",
"   </p>",
"   <p>",
"    It is likely that aldosterone plays an important role as the fine modulator of Na+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/14\">",
"     14",
"    </a>",
"    ]. As illustrated in this figure (",
"    <a class=\"graphic graphic_figure graphicRef78411 \" href=\"UTD.htm?21/10/21678\">",
"     figure 1",
"    </a>",
"    ), renin and aldosterone release vary inversely with relatively minor changes in Na+ intake. There is also evidence that the natriuretic response to a relatively small increase in Na+ intake is associated with a rise in ANP release [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], although the physiologic role of ANP remains to be proven [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Since aldosterone and ANP affect Na+ reabsorption in the collecting tubules, this segment may be the primary site at which volume regulation is achieved in normal humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=see_link\">",
"     \"Chapter 6D: Natriuretic peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although proximal function cannot be measured directly in humans, studies monitoring changes in urate excretion suggest that changes in volume may be associated with alterations in proximal reabsorption. Net urate reabsorption occurs in the proximal tubule by a process that appears to be mediated by parallel Na+-H+ and urate--anion exchangers (",
"    <a class=\"graphic graphic_figure graphicRef62014 \" href=\"UTD.htm?35/51/36669\">",
"     figure 2",
"    </a>",
"    ). Volume depletion, as occurs with diuretic therapy for example, is often associated with decreased urate excretion and hyperuricemia, suggesting that there has been an increase in overall proximal Na+ and urate transport [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/18\">",
"     18",
"    </a>",
"    ]. On the other hand, the urate wasting and hypouricemia commonly seen in the syndrome of inappropriate ADH secretion is related in part to the associated water retention and volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Redundancy of control systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the probable importance of aldosterone in Na+ excretion, abnormalities in the secretion of this hormone are not usually associated with disturbances in Na+ balance because other factors are able to compensate. As an example, adrenalectomized patients treated with replacement doses of a mineralocorticoid are able to maintain Na+ balance, even though they are unable to vary the level of mineralocorticoid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/20\">",
"     20",
"    </a>",
"    ]. Similarly, subjects given aldosterone or patients with an autonomous, aldosterone-secreting adrenal adenoma retain fluid for only a few days and then undergo a spontaneous diuresis that returns the volume status toward normal. This phenomenon of",
"    <strong>",
"     aldosterone escape",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef62044 \" href=\"UTD.htm?28/29/29150\">",
"     figure 3",
"    </a>",
"    ) is due to decreased Na+ reabsorption at some other site in the nephron, a response that may be mediated in part by ANP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] and by a direct effect of the rise in renal perfusion pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar considerations in terms of the redundant regulation of Na+ balance appear to apply to ANP. Studies in animals made ANP-deficient by immunization or by blocking the renal action of ANP have demonstrated an impairment in the natriuretic response to acute volume expansion, but not to chronic hypervolemia as induced by a high salt intake with or without a mineralocorticoid [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]. On the other hand, transgenic mice given an extra ANP gene have plasma ANP levels that are 10 times normal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/24\">",
"     24",
"    </a>",
"    ]. Nevertheless, Na+ excretion is still equal to intake, perhaps due in part to the concurrent fall in blood pressure that limits the natriuretic response to ANP. Thus, ANP may contribute to but is not necessary for the maintenance of Na+ balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pressure natriuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An essential \"back-up\" feature of the volume regulatory system that can compensate for an abnormality in the humoral control of Na+ excretion is the phenomenon of pressure natriuresis (",
"    <a class=\"graphic graphic_figure graphicRef62044 \" href=\"UTD.htm?28/29/29150\">",
"     figure 3",
"    </a>",
"    ). In normal subjects, a small elevation in blood pressure results in a relatively large increase in the urinary excretion of Na+ and water [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In contrast to the other mediators of tubular Na+ transport, this pressure natriuresis phenomenon does not require neurally or humorally mediated sensor mechanisms, since changes in volume directly affect the cardiac output and therefore the systemic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which pressure natriuresis occurs is incompletely understood, as decreased reabsorption in the proximal tubule and loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/8,28-30\">",
"     8,28-30",
"    </a>",
"    ]. It is possible, for example, that the increase in systemic pressure is transmitted, via the vasa recta capillaries, to the medullary interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/8,30\">",
"     8,30",
"    </a>",
"    ]. This rise in interstitial pressure can impair NaCl transport in at least two ways [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increase in capillary pressure can diminish the movement of reabsorbed solutes and water from the interstitium into the capillary, thereby preventing their return to the systemic circulation.",
"     </li>",
"     <li>",
"      The elevation in interstitial pressure will tend to push fluid into the water-permeable",
"      <strong>",
"       descending",
"      </strong>",
"      limb of the loop of Henle, counteracting the osmotic gradient favoring water movement out of this segment into the hyperosmotic interstitium. The ensuing decline in descending limb water reabsorption &nbsp;will minimize the rise in the tubular fluid Na+ concentration that is required for subsequent passive NaCl transport in the thin ascending limb. The net effect is decreased loop NaCl reabsorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link&amp;anchor=H6#H6\">",
"       \"Chapter 4B: Countercurrent mechanism\", section on 'NaCl reabsorption in thin ascending limb'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased release of renal prostaglandins and more importantly nitric oxide may contribute to pressure natriuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/28,31-33\">",
"     28,31-33",
"    </a>",
"    ]. It is unclear if this represents a direct hormonal effect on tubular transport&dagger; or is mediated by renal vasodilatation with a subsequent increase in intracapillary pressure. These changes are reversed with a fall in renal perfusion pressure, as tubular sodium and water reabsorption are enhanced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/29,34\">",
"     29,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide (NO) release from the macula densa is a modulating factor that is augmented during increased sodium chloride delivery, thereby countering the afferent arteriole constriction elicited in the tubuloglomerular feedback (TGF) response. It has been suggested that enhanced macula densa NO production may underlie the resetting of TGF that occurs when salt intake is increased; the response is appropriately blunted in this setting, as maintenance of glomerular filtration promotes excretion of the excess salt&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &dagger; As described in Chapter 6, prostaglandins appear to inhibit Na+ reabsorption in the thick ascending limb and in the cortical collecting tubule. This effect is not important in the day-to-day regulation of Na+ excretion, since there is a low basal rate of prostaglandin production. The major stimuli to renal prostaglandin synthesis are the vasoconstrictors angiotensin II and norepinephrine, which are released in states of effective volume depletion. In this setting, the prostaglandins minimize both the renal ischemia and the associated Na+ retention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/966?source=see_link\">",
"     \"Chapter 6E: Prostaglandins and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the mechanism, pressure natriuresis can, in certain circumstances, play an important role in the maintenance of volume balance. It is not likely to contribute significantly to the day-to-day regulation of Na+ excretion, since changes in aldosterone and perhaps ANP release are sufficient to accomplish this goal. As an example, a 50-fold increase in Na+ intake and subsequent excretion (from very low to high levels) is associated with only a 4 mmHg elevation in systemic blood pressure in normal subjects (as shown in the middle curve as shown in this figure) (",
"    <a class=\"graphic graphic_figure graphicRef50178 \" href=\"UTD.htm?0/8/139\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/25\">",
"     25",
"    </a>",
"    ]. In this setting, the decline in angiotensin II and aldosterone and increase in ANP are sufficient to markedly increase Na+ excretion without requiring a large rise in blood pressure.",
"   </p>",
"   <p>",
"    If, however, there is an impairment in one or more of the neurohumoral mediators of volume regulation, then pressure natriuresis may be required to maintain Na+ balance. This concept can be illustrated by the changes induced by increasing sodium intake when the ability to regulate angiotensin II and aldosterone according to Na+ intake is impaired, either by very low or by very high angiotensin II levels (left and right curves as shown in this figure) (",
"    <a class=\"graphic graphic_figure graphicRef50178 \" href=\"UTD.htm?0/8/139\">",
"     figure 4",
"    </a>",
"    ). In both cases, tubular Na+ reabsorption cannot be decreased by diminishing the production of angiotensin II and aldosterone; as a result, a greater than normal increase in blood pressure is required to maintain Na+ balance as intake is increased.",
"   </p>",
"   <p>",
"    These experiments illustrate the role of pressure natriuresis in the regulation of blood pressure as well as that of Na+ excretion. This can also be illustrated by the phenomenon of aldosterone escape [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/21\">",
"     21",
"    </a>",
"    ]. The initial Na+ retention and elevation in systemic blood pressure induced by aldosterone is followed by a spontaneous natriuresis that minimizes the degree of volume expansion and hypertension (",
"    <a class=\"graphic graphic_figure graphicRef62044 \" href=\"UTD.htm?28/29/29150\">",
"     figure 3",
"    </a>",
"    ). Although the diuresis in this setting may in part be mediated by increased release of ANP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], pressure natriuresis also appears to play an important role. As shown in this figure (",
"    <a class=\"graphic graphic_figure graphicRef73932 \" href=\"UTD.htm?6/52/6991\">",
"     figure 5",
"    </a>",
"    ), use of a suprarenal aortic clamp to maintain a constant renal perfusion pressure prevents aldosterone escape from occurring. The net effect is continued Na+ retention and the eventual development of pulmonary edema or malignant hypertension. Release of the clamp is rapidly followed by increased urinary Na+ loss and a reduction in the systemic blood pressure.",
"   </p>",
"   <p>",
"    This observation can be extended to any form of hypertension: the rise in blood pressure, whether induced by aldosterone, norepinephrine, or underlying renal disease, is eventually limited by fluid loss induced by pressure natriuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In terms of Figure 4 (",
"    <a class=\"graphic graphic_figure graphicRef50178 \" href=\"UTD.htm?0/8/139\">",
"     figure 4",
"    </a>",
"    ), the pressure natriuresis curve is shifted to the right in hypertensive patients; that is, Na+ balance is maintained, but at a higher than normal systemic blood pressure to overcome, for example, the Na+-retaining effect of aldosterone.",
"   </p>",
"   <p>",
"    Pressure natriuresis can also limit Na+ excretion when renal perfusion pressure is reduced by effective volume depletion due, for example, to diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/27\">",
"     27",
"    </a>",
"    ]. The sodium-retaining effect in this setting is normally mediated by angiotensin II and norepinephrine as described above. If, however, both systems are blocked, sodium retention still occurs in association with a fall in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/38\">",
"     38",
"    </a>",
"    ]. The fall in blood pressure, which can enhance Na+ reabsorption by pressure natriuresis, is due to the absence of angiotensin II and norepinephrine mediated vasoconstriction which maintains the blood pressure in hypovolemic subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure natriuresis can also explain the variable effects of sympathetic blockade on renal Na+ handling. As described above, increased sympathetic activity raises the systemic blood pressure and enhances proximal Na+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The net effect on Na+ excretion, however, is not predictable, since the elevation in renal perfusion pressure will tend to counteract the direct tubular effect [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/42\">",
"     42",
"    </a>",
"    ]. In effective volume depletion, for example, the increase in adrenergic tone appropriately raises the systemic blood pressure; this would also lead to inappropriate urinary Na+ wasting if it were not for the concurrent increase in Na+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interaction between the pressure and reabsorptive effects of the sympathetic nervous system can also be illustrated by the response to the sympatholytic agent, guanethidine (a now rarely used antihypertensive drug). When given in doses that do not reduce the systemic pressure, guanethidine can inhibit the adrenergic action on the kidney, resulting in an increase in Na+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/43\">",
"     43",
"    </a>",
"    ]. However, when guanethidine is used to lower the blood pressure in patients with hypertension, the hypotensive effect predominates and Na+ retention is likely to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. This constitutes the rationale for the use of diuretics in combination with sympathetic blockers in the treatment of hypertension, since the increase in volume produced by the latter tends to minimize the hypotensive response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Also complicating the evaluation of the sympathetic effect on Na+ excretion is the demonstration that renal sympathetic tone may occasionally be regulated independent of that in other organs. This phenomenon appears to be mediated by volume receptors in the left side of the heart, as an increase in left-sided pressure results in a",
"    <strong>",
"     reduction in renal sympathetic tone",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/46-48\">",
"     46-48",
"    </a>",
"    ], even though total sympathetic activity may be enhanced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of this cardiorenal reflex is illustrated by the following animal experiment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/48\">",
"     48",
"    </a>",
"    ]. The induction of hypotensive hemorrhage (which lowers left-sided pressures) resulted in a decrease in renal blood flow of as much as 90 percent and a cessation of urine output, both of which were due in large part to a hypotension-induced increase in sympathetic activity and subsequent marked renal vasoconstriction. In contrast, a similar reduction in systemic blood pressure due to an acute myocardial infarction (which raises left-sided pressures) was associated with only a 25 percent fall in renal blood flow and persistence of an adequate urine output. This relative maintenance of renal perfusion and urine flow presumably was due in part to reduced renal sympathetic tone, resulting from the elevation in left-sided intracardiac pressure. It is also possible that increased secretion of ANP contributed to the relative renal vasodilation in this setting.",
"   </p>",
"   <p>",
"    Although it is uncertain how important the left-sided cardiac receptors are in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/49\">",
"     49",
"    </a>",
"    ], a cardiorenal reflex can explain the clinical observation that postischemic acute tubular necrosis frequently follows hypotension due to sepsis, surgery, or hemorrhage, but is rare when renal hypoperfusion is due to heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma Na+ concentration &mdash; Urinary Na+ excretion also may be affected by the plasma Na+ concentration, tending to increase with hypernatremia and to fall with hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. This effect may be mediated both by changes in the filtered Na+ load (GFR times plasma Na+ concentration) and in the rate of tubular reabsorption. These responses can be viewed as appropriate from the viewpoint of maintenance of the plasma Na+ concentration. Increasing Na+ excretion with hypernatremia, for example, will tend to lower the plasma Na+ concentration toward normal.",
"   </p>",
"   <p>",
"    However, the plasma Na+ concentration does not play an important role in the daily regulation of Na+ excretion, since it is normally maintained within narrow limits by ADH and thirst. Furthermore, even in patients who are hyponatremic or hypernatremic, the effective circulating volume is a more important determinant of Na+ excretion than the plasma Na+ concentration &nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3922?source=see_link\">",
"     \"Chapter 8D: Volume regulation versus osmoregulation\"",
"    </a>",
"    ). As an example, the syndrome of inappropriate ADH secretion is characterized by water retention, which leads to both hyponatremia and volume expansion. As a result, this disorder is initially associated with enhanced Na+ excretion, although the increase may be somewhat less than that seen with an equivalent degree of volume expansion in a patient with a normal plasma Na+ concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/54\">",
"     54",
"    </a>",
"    ]. Similarly, urinary Na+ excretion is reduced in hypernatremic patients who are volume-depleted due, for example, to lack of replacement of insensible water losses from the skin and respiratory tract (see Chap. 24).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is clear that multiple factors affect renal Na+ excretion and therefore the regulation of the effective circulating volume. It seems likely that aldosterone and possibly atrial natriuretic peptide (or related peptides such as urodilatin) are responsible for day-to-day variations in Na+ excretion, by their respective ability to augment and diminish Na+ reabsorption in the collecting tubules. As Na+ intake is reduced, for example, the ensuing decrease in volume enhances the activity of the renin-angiotensin-aldosterone system and reduces the secretion of ANP. The net effect is enhanced Na+ reabsorption in the collecting tubules, which seems to account for the appropriate fall in Na+ excretion in this setting. With more marked hypovolemia, a decrease in GFR and increase in proximal and thin ascending limb Na+ reabsorption also contribute to Na+ retention. Both angiotensin II and norepinephrine may contribute to this response, which is clinically important because the stimulation of proximal transport also increases the reabsorption of bicarbonate and urate (see Chap. 3). Consequently, hypovolemia can lead to the maintenance of metabolic alkalosis (because the excess bicarbonate cannot be excreted) and to hyperuricemia and gout, all of which commonly occur in patients receiving diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This sequence is reversed with volume expansion, as an increase in the secretion of ANP and a reduction in that of aldosterone (Fig. 8-3) allow excretion of the excess Na+ by diminishing collecting tubule Na+ reabsorption. With more pronounced hypervolemia, reabsorption may also fall in the proximal tubule, often leading to enhanced urate secretion and hypouricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pressure natriuresis phenomenon may be the",
"    <strong>",
"     final defense",
"    </strong>",
"    against changes in the effective circulating volume [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In normal subjects, it probably plays a relatively minor role, because the other regulatory systems are sufficiently sensitive to maintain Na+ balance without a large change in extracellular volume or blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/25\">",
"     25",
"    </a>",
"    ]. If, however, there is an abnormality in one or more of these factors (as with renal disease or excess angiotensin II or aldosterone), the degree of Na+ retention that will occur is ultimately limited, since the ensuing volume expansion raises the blood pressure, which then enhances Na+ excretion. Eventually, a new steady state is reestablished in which intake and excretion are equal and the blood pressure is higher than normal.",
"   </p>",
"   <p>",
"    Sodium reabsorption in the distal tubule and the thick ascending limb of the loop of Henle is primarily flow-dependent and not influenced by hormones involved in volume regulation (see Chaps. 6 and 7). As a result, changes in transport in these segments usually do not play an important role in regulating Na+ excretion. One exception to this general rule occurs in patients treated with a loop diuretic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . The reduction in loop reabsorption in this setting increases fluid delivery to the distal tubule, leading to an enhanced rate of distal Na+ reabsorption (and the requisite rise in activity of the Na+-K+-ATPase pump that returns reabsorbed Na+ to the systemic circulation) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Similarly, blocking distal tubule Na+ reabsorption with a thiazide-type diuretic leads to increased downstream Na+ transport in the cortical collecting tubule, which also can respond to changes in flow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6744/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These compensatory adaptations may be important because they limit the net response to the diuretic. In most cases, an adequate diuresis is still obtained. However, increased distal reabsorption can induce",
"    <strong>",
"     diuretic resistance",
"    </strong>",
"    in some patients, who may require combined therapy with a loop and thiazide diuretic to inhibit transport at several sites in the nephron (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=see_link\">",
"     \"Treatment of refractory edema in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This discussion is continued elsewhere (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3922?source=see_link\">",
"     \"Chapter 8D: Volume regulation versus osmoregulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/1\">",
"      Lindheimer MD, Lalone RC, Levinsky NG. Evidence that an acute increase in glomerular filtration has little effect on sodium excretion in the dog unless extracellular volume is expanded. J Clin Invest 1974; 46:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/2\">",
"      Bricker NS, Fine LG, Kaplan M, et al. \"Magnification phenomenon\" in chronic renal disease. N Engl J Med 1978; 299:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/3\">",
"      Wright FS. Flow-dependent transport processes: filtration, absorption, secretion. Am J Physiol 1982; 243:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/4\">",
"      Greger R, Vel&aacute;zquez H. The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism. Kidney Int 1987; 31:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/5\">",
"      Stein JH, Osgood RW, Boonjarern S, et al. Segmental sodium reabsorption in rats with mild and severe volume depletion. Am J Physiol 1974; 227:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/6\">",
"      Weiner MW, Weinman EJ, Kashgarian M, Hayslett JP. Accelerated reabsorption in the proximal tubule produced by volume depletion. J Clin Invest 1971; 50:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/7\">",
"      Moe OW, Tejedor A, Levi M, et al. Dietary NaCl modulates Na(+)-H+ antiporter activity in renal cortical apical membrane vesicles. Am J Physiol 1991; 260:F130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/8\">",
"      Cowley AW Jr. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 1997; 273:R1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/9\">",
"      Faubert PF, Chou SY, Porush JG, et al. Papillary plasma flow and tissue osmolality in chronic caval dogs. Am J Physiol 1982; 242:F370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/10\">",
"      Osgood RW, Reineck HJ, Stein JH. Further studies on segmental sodium transport in the rat kidney during expansion of the extracellular fluid volume. J Clin Invest 1978; 62:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/11\">",
"      DIRKS JH, CIRKSENA WJ, BERLINER RW. THE EFFECTS OF SALINE INFUSION ON SODIUM REABSORPTION BY THE PROXIMAL TUBULE OF THE DOG. J Clin Invest 1965; 44:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/12\">",
"      Knox FG, Burnett JC Jr, Kohan DE, et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Int 1980; 17:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/13\">",
"      Simpson FO. Sodium intake, body sodium, and sodium excretion. Lancet 1988; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/14\">",
"      Sagnella GA, Markandu ND, Buckley MG, et al. Hormonal responses to gradual changes in dietary sodium intake in humans. Am J Physiol 1989; 256:R1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/15\">",
"      Homcy C, Gaivin R, Zisfein J, Graham RM. Snack-induced release of atrial natriuretic peptide (letter). N Engl J Med 1984; 313:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/16\">",
"      de Zeeuw D, Janssen WM, de Jong PE. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int 1992; 41:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/17\">",
"      Goetz KL. Evidence that atriopeptin is not a physiological regulator of sodium excretion. Hypertension 1990; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/18\">",
"      Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med 1969; 47:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/19\">",
"      Beck LH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1979; 301:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/20\">",
"      Rosenbaum JD, Papper S, Ashley MM. Variations in renal excretion of sodium independent of change in adrenocortical hormone dosage in patients with Addison's disease. J Clin Endocrinol Metab 1955; 15:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/21\">",
"      Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/22\">",
"      Yokota N, Bruneau BG, Kuroski de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994; 94:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/23\">",
"      Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone \"escape\". Hypertension 1984; 6 (suppl I):I-183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/24\">",
"      Field LJ, Veress AT, Steinhelper ME, et al. Kidney function in ANF-transgenic mice: effect of blood volume expansion. Am J Physiol 1991; 260:R1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/25\">",
"      Guyton AC. Blood pressure control--special role of the kidneys and body fluids. Science 1991; 252:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/26\">",
"      Hall JE, Mizelle HL, Hildebrandt DA, Brands MW. Abnormal pressure natriuresis. A cause or a consequence of hypertension? Hypertension 1990; 15:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/27\">",
"      Mizelle HL, Montani JP, Hester RL, et al. Role of pressure natriuresis in long-term control of renal electrolyte excretion. Hypertension 1993; 22:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/28\">",
"      Roman RJ. Pressure-diuresis in volume-expanded rats. Tubular reabsorption in superficial and deep nephrons. Hypertension 1988; 12:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/29\">",
"      Kinoshita Y, Knox FG. Role of prostaglandins in proximal tubule sodium reabsorption: response to elevated renal interstitial hydrostatic pressure. Circ Res 1989; 64:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/30\">",
"      Granger JP. Pressure natriuresis: Role of renal interstitial hydrostatic pressure. Hypertension 1992; 19 (suppl I):I-9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/31\">",
"      Carmines PK, Bell PD, Roman RJ, et al. Prostaglandins in the sodium excretory response to altered renal arterial pressure in dogs. Am J Physiol 1985; 248:F8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/32\">",
"      Salom MG, Lahera V, Miranda-Guardiola F, Romero JC. Blockade of pressure natriuresis induced by inhibition of renal synthesis of nitric oxide in dogs. Am J Physiol 1992; 262:F718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/33\">",
"      Guarasci GR, Kline RL. Pressure natriuresis following acute and chronic inhibition of nitric oxide synthase in rats. Am J Physiol 1996; 270:R469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/34\">",
"      Levy M. Effects of acute volume expansion and altered hemodynamics on renal tubular function in chronic caval dogs. J Clin Invest 1972; 51:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/35\">",
"      Wilcox CS, Welch WJ. TGF and nitric oxide: effects of salt intake and salt-sensitive hypertension. Kidney Int Suppl 1996; 55:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/36\">",
"      Cappuccio FP, Markandu ND, Buckley MG, et al. Changes in the plasma levels of atrial natriuretic peptides during mineralocorticoid escape in man. Clin Sci (Lond) 1987; 72:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/37\">",
"      Ballermann BJ, Bloch KD, Seidman JG, Brenner BM. Atrial natriuretic peptide transcription, secretion, and glomerular receptor activity during mineralocorticoid escape in the rat. J Clin Invest 1986; 78:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/38\">",
"      Wilcox CS, Guzman NJ, Mitch WE, et al. Na+, K+, and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int 1987; 31:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/39\">",
"      DiBona GF. Renal neural activity in hepatorenal syndrome. Kidney Int 1984; 25:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/40\">",
"      Osborn JL, Holdaas H, Thames MD, DiBona GF. Renal adrenoceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog. Circ Res 1983; 53:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/41\">",
"      Gill JR Jr, Casper AG. Role of the sympathetic nervous system in the renal response to hemorrhage. J Clin Invest 1969; 48:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/42\">",
"      Ehmke H, Persson PB, Seyfarth M, Kirchheim HR. Neurogenic control of pressure natriuresis in conscious dogs. Am J Physiol 1990; 259:F466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/43\">",
"      GILL JR Jr, MASON DT, BARTTER FC. ADRENERGIC NERVOUS SYSTEM IN SODIUM METABOLISM: EFFECTS OF GUANETHIDINE AND SODIUM-RETAINING STEROIDS IN NORMAL MAN. J Clin Invest 1964; 43:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/44\">",
"      Dustan HP, Tarazi RC, Bravo EL. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med 1972; 286:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/45\">",
"      SMITH AJ. FLUID RETENTION PRODUCED BY GUANETHIDINE; CHANGES IN BODY EXCHANGEABLE SODIUM, BLOOD VOLUME, AND CREATININE CLEARANCE. Circulation 1965; 31:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/46\">",
"      Thames MD, Abboud FM. Reflex inhibition of renal sympathetic nerve activity during myocardial ischemia mediated by left ventricular receptors with vagal afferents in dogs. J Clin Invest 1979; 63:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/47\">",
"      Thames MD, Miller BD, Abboud FM. Baroreflex regulation of renal nerve activity during volume expansion. Am J Physiol 1982; 243:H810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/48\">",
"      Gorfinkel HJ, Szidon JP, Hirsch LJ, Fishman AP. Renal performance in experimental cardiogenic shock. Am J Physiol 1972; 222:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/49\">",
"      Cornish KG, Gilmore JP. Increased left atrial pressure does not alter renal function in the conscious primate. Am J Physiol 1982; 243:R119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/50\">",
"      Schrier RW. Nephrology forum: acute renal failure. Kidney Int 1979; 15:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/51\">",
"      Metzler GH, Thrasher TN, Keil LC, Ramsay DJ. Endocrine mechanisms regulating sodium excretion during water deprivation in dogs. Am J Physiol 1986; 251:R560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/52\">",
"      Langberg H, Hartmann A, Ostensen J, et al. Hypernatremia inhibits NaHCO3 reabsorption and associated NaCl reabsorption in dogs. Kidney Int 1986; 29:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/53\">",
"      Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: influence of factors other than aldosterone and glomerular filtration rate. 1. N Engl J Med 1971; 285:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/54\">",
"      Schrier RW, Fein RL, McNeil JS, Cirksena WJ. Influence of interstitial fluid volume expansion and plasma sodium concentration on the natriuretic response to volume expansion in dogs. Clin Sci 1969; 36:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/55\">",
"      Scherzer P, Wald H, Popovtzer MM. Enhanced glomerular filtration and Na+-K+-ATPase with furosemide administration. Am J Physiol 1987; 252:F910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/56\">",
"      Hropot M, Fowler N, Karlmark B, Giebisch G. Tubular action of diuretics: distal effects on electrolyte transport and acidification. Kidney Int 1985; 28:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/57\">",
"      Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6744/abstract/58\">",
"      Garg LC, Narang N. Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron. Kidney Int 1987; 31:918.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7270 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6744=[""].join("\n");
var outline_f6_37_6744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOMERULAR FILTRATION RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TUBULAR REABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Day-to-day regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Redundancy of control systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pressure natriuresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7270|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/10/21678\" title=\"figure 1\">",
"      Renin aldosterone and sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/51/36669\" title=\"figure 2\">",
"      Proximal uric acid reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/29/29150\" title=\"figure 3\">",
"      Resumption of the steady state in primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/8/139\" title=\"figure 4\">",
"      Pressure natriuresis and BP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/52/6991\" title=\"figure 5\">",
"      Aldosterone escape II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7270|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/3/20539\" title=\"table 1\">",
"      Segmental Na reabsorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=related_link\">",
"      Chapter 3A: Cell model for proximal transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=related_link\">",
"      Chapter 6D: Natriuretic peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/966?source=related_link\">",
"      Chapter 6E: Prostaglandins and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3922?source=related_link\">",
"      Chapter 8D: Volume regulation versus osmoregulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/40/650?source=related_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_37_6745="NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity";
var content_f6_37_6745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6745/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6745/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/37/6745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/37/6745/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/37/6745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2782934\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) are in use throughout the world (",
"    <a class=\"graphic graphic_table graphicRef54253 \" href=\"UTD.htm?38/16/39180\">",
"     table 1",
"    </a>",
"    ). NSAIDs are popular because of their versatile effectiveness as analgesics, antipyretics, and as antiinflammatory agents.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is also used as an anti-thrombotic agent. Unfortunately, aspirin and most other NSAIDs can injure the gastric and duodenal mucosa, with considerable morbidity and mortality.",
"   </p>",
"   <p>",
"    The pathogenesis and clinical manifestations of gastroduodenal toxicity attributed to the use of NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    will be reviewed here. Other topics, such as other side effects, including injury to the small and large intestine, recommendations for the prevention and treatment of NSAID-induced gastroduodenal injury, and an overview of selective COX-2 inhibitors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=see_link\">",
"     \"NSAIDs: Adverse effects on the distal small bowel and colon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTEMIC VERSUS TOPICAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and many other NSAIDs are carboxylic acid derivatives [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, they are not ionized at the acidic pH found in the gastric lumen and thus can be absorbed across the gastric mucosa. Once the drug moves from the acidic environment of the gastric lumen into the pH&ndash;neutral mucosa, the drug ionizes and is trapped temporarily in epithelial cells where it may damage these cells.",
"   </p>",
"   <p>",
"    However, this \"topical\" epithelial injury by many NSAIDs does not appear to be of prime importance in the pathogenesis of clinically important endpoints (symptomatic ulcers) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/2\">",
"     2",
"    </a>",
"    ]. The pathogenesis of symptomatic peptic ulcer disease caused by exposure to NSAIDs is mainly a consequence of systemic (post-absorptive) inhibition of GI mucosal cyclooxygenase (COX) activity. Even intravenous or intramuscular administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAIDs can cause gastric or duodenal ulcers in animals and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE CENTRAL ROLE OF CYCLOOXYGENASE PRODUCTS (PROSTAGLANDINS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;COX, the rate-limiting enzyme in prostaglandin (PG) synthesis, converts the unsaturated fatty acid arachidonic acid (C20:4) (derived from phospholipids in cell membranes) into PGG2 and then to PGH2 (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    ). The gastric and duodenal mucosa proceed to convert PGH2 to various prostanoids (prostaglandins and thromboxane A2) PGs such as PGE2 protect the mucosal lining from injury by luminal acid-pepsin.",
"   </p>",
"   <p>",
"    There are at least two forms of COX in the body, COX-1 and COX-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/1\">",
"     1",
"    </a>",
"    ]. These two proteins are 50 to 60 percent homologous and are coded on different chromosomes. COX-1 is a constitutive enzyme with a fairly steady rate of expression in most cells of the body. In contrast, COX-2 is expressed in many cells only when bacterial polysaccharides, pro-inflammatory cytokines such as TNFa or IL-1b, or growth factors (mitogens) induce its expression. The brain, heart, and aorta also express a variant form of COX-1, dubbed COX-3, with levels in brain tissue around 5 percent of those of COX-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/1\">",
"     1",
"    </a>",
"    ]. COX-3 in the brain may be one target of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The healthy gastric and duodenal mucosa constitutively use COX-1 to produce its mucosal-protective PGs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/7\">",
"     7",
"    </a>",
"    ]. Many NSAIDs block COX-1 and COX-2 more or less equally (ie, are non-selective) and thus may impair gastric PG production at low (&lt;1&micro;M) concentrations (",
"    <a class=\"graphic graphic_table graphicRef54253 \" href=\"UTD.htm?38/16/39180\">",
"     table 1",
"    </a>",
"    ). Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    . Drugs that more selectively inhibit COX-2 than COX-1 have less suppressive effects on gastric PG synthesis (",
"    <a class=\"graphic graphic_table graphicRef54253 \" href=\"UTD.htm?38/16/39180\">",
"     table 1",
"    </a>",
"    ). Examples include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/35/13881?source=see_link\">",
"     etodolac",
"    </a>",
"    . As a result, selective inhibitors of COX-2, and also COX&ndash;3 inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , preserve PG-mediated GI mucosal protection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, COX-2 selective inhibitors may still block COX-1 at clinically recommended doses and thus have the potential to also block COX-1 in the stomach and duodenum and cause damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISMS OF GASTRODUODENAL PROTECTION BY ENDOGENOUS PGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many mucosal functions are altered by endogenous PGs and by exogenously administered PGs; these changes may contribute to the mucosal protective effects of PGs. While it is true that certain PGs such as PGE2 reduce gastric acid secretion, hypochlorhydria does not entirely explain the mucosal protection observed with PGE2. In animals, for example, doses of PGE2 far too low to inhibit gastric acid secretion profoundly protect against gastric injury induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , alcohol, and other gastric irritants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/11\">",
"     11",
"    </a>",
"    ]. This non-antisecretory effect of PGs has been referred to as \"cytoprotection\". Some of the cytoprotective mechanisms of PGs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stimulation of glycoprotein (mucin) secretion by epithelial cells",
"     </li>",
"     <li>",
"      Stimulation of bicarbonate secretion by epithelial cells",
"     </li>",
"     <li>",
"      Stimulation of phospholipid secretion by epithelial cells",
"     </li>",
"     <li>",
"      Enhancement of mucosal blood flow and oxygen delivery to epithelial cells via local vasodilation",
"     </li>",
"     <li>",
"      Increased epithelial cell migration towards the luminal surface (restitution)",
"     </li>",
"     <li>",
"      Enhanced epithelial cell proliferation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two mechanisms, stimulation of epithelial mucin and bicarbonate secretion, combine to form an alkaline, unstirred water layer on the surface of the gastric mucosa, which retards diffusion of acid-pepsin from the lumen into the mucosa. Gastric and duodenal injury by acid and pepsin occurs when the protective functions are compromised as a consequence of PG deficiency induced by a COX-1 inhibiting NSAID or, experimentally, by antibodies to PGs. This damage may eventually lead to gastric",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenal ulcer formation, with or without serious ulcer complications (bleeding, perforation, and obstruction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ROLE OF NITRIC OXIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generation of nitric oxide (NO) may be a key intermediate in cytoprotection. Similar to the role of COX-1, constitutive NO synthase (NOS) is important in the maintenance of an intact mucosal lining. Two enzymes contribute to the basal, constitutive NOS activity: neuronal NOS (nNOS, type I) and endothelial NOS (eNOS, type III). The cytoprotective mechanisms of NO parallel PG effects and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mediation of the release of gastric mucin",
"     </li>",
"     <li>",
"      Stimulation of alkaline fluid secretion",
"     </li>",
"     <li>",
"      Maintenance of epithelial barrier function",
"     </li>",
"     <li>",
"      Enhancement of mucosal blood flow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some but not all models, inducible NO synthase (iNOS, type II) produces high levels of NO leading to physiological responses that are often quite different than seen in the basal state. Inducible NOS is generally associated with inflammatory states, similar to COX-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the relationship between the various NOS and COX enzymes has not been fully elucidated. Most studies implicate both enzymes in the maintenance of gastric mucosal integrity as well as in epithelial restitution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Manipulation of NO levels in models of NSAID-induced mucosal damage suggest a protective role for both NO and PGs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the importance of NO in mucosal defense, NSAIDs coupled to NO itself or to NO donors have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/17\">",
"     17",
"    </a>",
"    ]. These novel compounds are undergoing evaluation in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPECTRUM OF GASTRODUODENAL MUCOSAL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the stomach or duodenum by NSAIDs can range from subtle alterations in gastric mucosal barrier function through microscopic damage to surface cells to gross injury visible through an endoscope or at the time of surgery for an ulcer complication.",
"   </p>",
"   <p>",
"    The most subtle change is disruption of mucosal barrier function, manifest as increased mucosal permeability to hydrogen ions (which then diffuse more rapidly from the lumen into the mucosa) and to sodium ions (which then diffuse more rapidly from the mucosa into the lumen). Disruption of the gastric mucosal barrier and the resultant damage to surface cells by gastric acid may result in macroscopic injury over time if repair mechanisms are ineffective.",
"   </p>",
"   <p>",
"    Repair mechanisms include rapid migration of deeper epithelial cells lining gastric pits to cover the damaged surface (restitution) and less rapid regeneration of new epithelial cells from progenitor cells (proliferation). Epithelial restitution and proliferation both require adequate amounts of well-oxygenated blood at a pH close to 7.4. PGs and NO have important roles in these repair mechanisms, while COX inhibitors can disrupt these PG-dependent reparative processes. Gastric restitution has been associated with induction of COX-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/19\">",
"     19",
"    </a>",
"    ]. The importance of the inhibition of COX-2 on gastric restitution in NSAID-induced injury is not yet known.",
"   </p>",
"   <p>",
"    Macroscopic injury by NSAIDs ranges from edema, erythema, subepithelial hemorrhage, erosions (mucosal breaks, without visible depth to the lesion), and ulcers (mucosal breaks, with visible depth to the lesion). Only",
"    <span class=\"nowrap\">",
"     erosive/ulcerative",
"    </span>",
"    lesions are considered clinically important, although lesser lesions may be precursors of erosive lesions if reparative mechanisms fail. Development of the full spectrum of lesions in the PG-depleted stomach or duodenum requires acid and pepsin; potent acid inhibition (eg, with PPIs) markedly protects against their development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastric damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GI mucosa uses COX-1 to generate mucosal-protective PGs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    doses as low as 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    inhibit gastric PG generation considerably and can damage the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/20\">",
"     20",
"    </a>",
"    ]. Epidemiologic and placebo-controlled studies indicate that the risk of serious, clinically-relevant GI damage increases as the aspirin dose is raised [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/8,21,22\">",
"     8,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy is stopped, the human stomach requires five to eight days to recover its COX-1 activity and its ability to synthesize protective PGs, suggesting a very slow turnover of gastric COX-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, gastric mucosa somewhat resembles the platelet, which requires 10 to 14 days to recover from aspirin.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    inhibits COX-1 and also COX-2, certain COX-2-mediated reactions can still occur after aspirin has been given, such as the conversion of arachidonic acid to the fatty acid 15-hydroxyeicosatetraenoic acid (15-HETE); 15-HETE is then converted to 15-epi lipoxin A4 by another enzyme, 5-lipoxygenase (5-LOX). Studies in animals have demonstrated enhanced production of 15-epi lipoxin A4 following aspirin exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/24\">",
"     24",
"    </a>",
"    ]. Furthermore, this lipoxin minimizes gastric damage by aspirin (ie, it is cytoprotective). This protective effect of 15-epi lipoxin A4 can be abolished &mdash; with more gastric damage resulting &mdash; by administering a selective COX-2 inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/24\">",
"     24",
"    </a>",
"    ]. Therefore, the combination of low-dose aspirin and a COX-2 selective inhibitor may lead to more GI damage than low-dose aspirin alone.",
"   </p>",
"   <p>",
"    In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , which acetylates COX irreversibly, most NSAIDs inhibit COX-1 and COX&ndash;2 reversibly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, even transient COX-1 inhibition in the gastric mucosa by an NSAID is sufficient to predispose the stomach to injury. That this injury is due to loss of PG-mediated cytoprotection is supported by the observation that NSAID-related gastric damage is prevented by PGE analogs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    does not primarily protect the stomach by inhibiting its ability to produce hydrochloric acid because drugs that inhibit gastric acid secretion to the same or slightly greater extent as misoprostol, such as histamine-2 receptor antagonists (H2RAs), have little or no protective effect against NSAID-induced gastric damage. On the other hand, the relative failure of H2RAs to protect the stomach from damage by NSAIDs can be overcome by using higher H2RA doses or by using more potent acid-inhibitory compounds such as the proton pump inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Duodenal damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    doses as low as 325 mg every other day increase the risk of duodenal ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast to the stomach, damage to the duodenal mucosa by aspirin and NSAIDs seems to depend highly upon gastric acid. Thus, not only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    but also by histamine-2 blockers with their modest acid inhibition can largely prevent endoscopic evidence of duodenal injury by NSAIDs. PPIs are also highly effective. These observations related to the pathogenesis of gastric and duodenal injury lay the groundwork for using either a PPI or misoprostol in the prevention of NSAID-induced gastroduodenal ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NSAID-INDUCED GASTRIC TOXICITY NOT MEDIATED THROUGH COX-1 INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While inhibition of COX-1 is the major mechanism by which NSAIDs produce gastric injury, mediators besides PGs (and NO) may also be involved. As an example, interference with factors that mediate restitution or adaptive protection may contribute to mucosal injury.",
"   </p>",
"   <p>",
"    Adaptive protection refers to the observation that mild gastric irritants induce enhanced cytoprotection. COX-1, COX-2, and NO as well as various growth factors, such as transforming growth factor (TGF)-beta and TGF-alpha, appear to participate in these adaptive processes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/27\">",
"     27",
"    </a>",
"    ]. Endogenous trefoil factor proteins are also associated with mucosal protection in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    -induced injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/28\">",
"     28",
"    </a>",
"    ]. NSAIDs probably interfere with growth factors and other mediators responsible for restitution and adaptive protection, further contributing to their toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ROLE OF HELICOBACTER PYLORI INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of Helicobacter pylori (H. pylori) infection in NSAID-induced gastritis or ulcer formation is complex [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/29-37\">",
"     29-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies of varying design have evaluated the relationship between NSAIDs and H. pylori in the development of peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/29,30,32,36,37\">",
"     29,30,32,36,37",
"    </a>",
"    ]. At least two meta-analyses concluded that NSAID use and H. pylori infection represent independent and synergistic risk factors for uncomplicated and bleeding peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In the more recent meta-analyses (with a total of 21 studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of uncomplicated peptic ulcer disease was significantly higher among H. pylori positive compared with H. pylori negative NSAID users (OR 1.81).",
"     </li>",
"     <li>",
"      Ulcers were common in H. pylori positive compared with H. pylori negative patients irrespective of NSAID use (OR 4.03) and in NSAID users compared with nonusers irrespective of H. pylori status (OR 3.10).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A related question is whether eradication of H. pylori prior to NSAID treatment can reduce the risk of PUD. At least four controlled trials have addressed this issue, but results have differed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/33-35,40\">",
"     33-35,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 92 patients with musculoskeletal pain, who were also infected with H. pylori, were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      alone (750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for eight weeks or to a one-week course of triple therapy for H. pylori followed by the same dose of naproxen [",
"      <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/33\">",
"       33",
"      </a>",
"      ]. After eight weeks, H. pylori was still present in all 47 patients in the naproxen-only group compared to only 5 of 45 patients (11 percent) in the triple-therapy group. Development of a peptic ulcer (defined as a mucosal break of 5 mm or more in diameter with a well-defined ulcer crater by endoscopy) was more common in the patients treated only with naproxen (26 versus 7 percent with anti-H. pylori therapy); two of the three patients in the latter group had failure of H. pylori eradication.",
"     </li>",
"     <li>",
"      A second trial (performed by the same authors) involved 102 patients with arthritis who were randomly assigned to eradication therapy or placebo eradication therapy followed by a six-month course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      slow release (100 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/34\">",
"       34",
"      </a>",
"      ]. Inclusion criteria required that patients had not previously been treated with a NSAID, had a positive urea breath test indicating H. pylori infection, had dyspepsia or an ulcer history, and required long-term NSAID treatment. During follow-up, the probability of endoscopically-detected ulcers was significantly higher in the placebo-treated group (34 versus 12 percent). The probability of complicated ulcers (defined as \"symptomatic or bleeding\") was also higher in the placebo group (27 versus 4 percent).",
"     </li>",
"     <li>",
"      A third trial randomly assigned 660 H. pylori-positive patients who were having musculoskeletal complaints that would require a NSAID for at least five weeks to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      for five weeks, diclofenac plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      for five weeks, diclofenac for five weeks and triple therapy for the first week, or diclofenac for five weeks with triple therapy for the first week followed by omeprazole for the next four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/40\">",
"       40",
"      </a>",
"      ]. All therapeutic strategies (H. pylori eradication, proton pump inhibitor therapy, or their combination) were equally effective in preventing endoscopically-detected NSAID ulcers and in reducing NSAID-related dyspeptic symptoms.",
"     </li>",
"     <li>",
"      Another trial included 285 patients already requiring therapy with NSAIDs, who were infected with H. pylori and had current or previous PUD, dyspepsia, or both [",
"      <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients were continued on their NSAID and randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      plus antibiotics for one week or omeprazole plus placebo for one week. Patients in both groups were equally likely to remain ulcer free at six months (56 versus 53 percent). Furthermore, fewer baseline gastric ulcers (but not duodenal ulcers) healed among patients who underwent H. pylori eradication. The failure of H. pylori eradication to enhance ulcer healing at six months was unexpected and unexplained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations regarding H. pylori testing in patients taking requiring NSAIDs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK OF GASTROINTESTINAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for the development of significant NSAID-induced gastrointestinal bleeding or perforation due to a peptic ulcer has been evaluated in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/26,41-56\">",
"     26,41-56",
"    </a>",
"    ]. An important determinant is the duration of therapy. The administration of NSAIDs for a short period of time (less than one week) in healthy people is unlikely to result in any significant gastroduodenal toxicity. Longer duration of therapy is associated with an increased risk of developing complications. On the other hand, gastroduodenal complications are most common within the first three months after the initiation of therapy. Gastroduodenal toxicity may develop even in patients taking low doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (such as for cardiovascular prophylaxis) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/56\">",
"     56",
"    </a>",
"    ], which, despite the low dose, can be associated with a significant decrease in gastric mucosal prostaglandin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H5#H5\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Besides duration of exposure, a number of other factors are associated with an increased risk of gastroduodenal toxicity and complications from NSAIDs. These include increasing age, higher NSAID dose(s), a past history of gastroduodenal toxicity from NSAIDs, a past history of peptic ulcer disease and concurrent use of glucocorticoids, anticoagulants, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (and probably of, bisphosphonates and selective serotonin reuptake inhibitors [SSRIs]) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/26,41,53,55-60\">",
"     26,41,53,55-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have suggested that SSRIs are associated with an increased risk of UGI bleeding, particularly in patients taking NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/57-59,61-64\">",
"     57-59,61-64",
"    </a>",
"    ]. A possible mechanism is platelet serotonin depletion, which may adversely influence the hemostatic response to vascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .) A systematic review found that the magnitude of the attributable risk was unclear and based upon weak evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the available data suggested that the risk was highest with concurrent use of SSRIs and NSAIDs or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (a 12- to 15-fold increase in risk of GI bleeding compared with a 2.8- to 1.7-fold increase with SSRIs alone). The authors suggested that the risk was of sufficient magnitude to warrant preventive measures (such as a PPI) in patients with other risk factors (advanced age or history of an upper gastrointestinal bleed) who are simultaneously prescribed an SSRI with a nonselective NSAID or aspirin.",
"   </p>",
"   <p>",
"    With respect to dose, the risk of toxicity with \"over-the-counter\" NSAIDs taken at recommended doses appears to be lower than with prescription NSAIDs (or over-the-counter NSAIDs used at doses comparable to a prescription dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of toxicity may not be uniform among the NSAIDs. Many studies of varying design have described gastrointestinal toxicity of different NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H3#H3\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Nonselective NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic predisposition due to polymorphism of cytochrome P450 2C9 may delay the metabolism of several NSAIDs, with a prolonged duration of drug enhancing the ulcerogenic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/60\">",
"     60",
"    </a>",
"    ]. Whether these variations can be used to modify care in individual patients has not yet been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     American College of Gastroenterology recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Gastroenterology had issued guidelines for risk stratifying patients with regard to NSAID-related GI toxicity (",
"    <a class=\"graphic graphic_table graphicRef71256 \" href=\"UTD.htm?25/4/25675\">",
"     table 2",
"    </a>",
"    ). These guidelines are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RELATIONSHIP BETWEEN DYSPEPTIC SYMPTOMS AND GASTRODUODENAL MUCOSAL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the biochemical, microscopic and macroscopic gastric lesions caused by NSAIDs produce very little in the way of symptoms. On the other hand,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and many NSAIDs, and even",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/10\">",
"     10",
"    </a>",
"    ], may produce dyspeptic symptoms (epigastric discomfort, upper abdominal pain, nausea, epigastric fullness or bloating), especially as the dose of the drug is increased.",
"   </p>",
"   <p>",
"    There is little correlation between the dyspeptic symptoms sometimes seen with these drugs and the presence or absence of",
"    <span class=\"nowrap\">",
"     erosive/ulcerative",
"    </span>",
"    lesions in the stomach and duodenum. Two examples illustrate this point. First, patients may present with severe ulcer complications from an NSAID with no preceding dyspeptic \"warning\" symptoms. Second,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and salicylsalicylic acid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    ) commonly produce dyspepsia, especially when used in higher doses, but neither blocks gastric COX activity over a wide range of doses or causes damage to the gastric mucosa (",
"    <a class=\"graphic graphic_table graphicRef54253 \" href=\"UTD.htm?38/16/39180\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/37/6745/abstract/7,10,67\">",
"     7,10,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations emphasize that studies evaluating gastric and duodenal toxicity of NSAIDs should not include dyspepsia as a part of a combined GI endpoint. In most instances the mechanism for the drug-related dyspepsia has not been determined. Dyspepsia and ulcer formation should be viewed as separate issues when using analgesic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucosal damage by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and NSAIDs is primarily a consequence of inhibition of COX-1 in the upper GI tract. COX-1 inhibition reduces mucosal generation of protective prostaglandins such as PGE2. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'The central role of cyclooxygenase products (prostaglandins)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanisms of gastroduodenal protection by endogenous PGs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration and dose of NSAIDs, increasing age, a past history of gastroduodenal toxicity from NSAIDs, peptic ulcer disease, and concurrent use of glucocorticoids, anticoagulants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and, possibly, bisphosphonates and selective serotonin reuptake inhibitors are associated with an increased risk of gastroduodenal toxicity and complications from NSAIDs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk of gastrointestinal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies to avoid mucosal damage include using antiinflammatory or analgesic drugs that have minimal effects on COX-1 at usual doses, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , or non-acetylated salicylates, or a selective COX-2 inhibitor, and prescribing either a potent inhibitor of gastric acid production such as a proton pump inhibitor or a prostaglandin E analog such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      together with the NSAID. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk of gastrointestinal complications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These strategies, though effective, are expensive and may not be cost-effective and in the case of selective COX-2 inhibitors may impart an increased risk of cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/1\">",
"      Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/2\">",
"      van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008; 6:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/3\">",
"      Hansen DG, Aures D, Grossman MI. Histamine augments gastric ulceration produced by intravenous aspirin in cats. Gastroenterology 1978; 74:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/4\">",
"      Estes LL, Fuhs DW, Heaton AH, Butwinick CS. Gastric ulcer perforation associated with the use of injectable ketorolac. Ann Pharmacother 1993; 27:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/5\">",
"      Wolfe PA, Polhamus CD, Kubik C, et al. Giant duodenal ulcers associated with the postoperative use of ketorolac: report of three cases. Am J Gastroenterol 1994; 89:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/6\">",
"      Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 2000; 31 Suppl 5:S202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/7\">",
"      Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/8\">",
"      Jick H. Effects of aspirin and acetaminophen in gastrointestinal hemorrhage. Results from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 1981; 141:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/9\">",
"      Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding. J Epidemiol Biostat 2000; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/10\">",
"      Lanza FL, Codispoti JR, Nelson EB. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen. Am J Gastroenterol 1998; 93:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/11\">",
"      Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/12\">",
"      Wallace JL, Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000; 119:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/13\">",
"      Whittle BJ, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/14\">",
"      Whittle BJ, Lopez-Belmonte J. Actions and interactions of endothelins, prostacyclin and nitric oxide in the gastric mucosa. J Physiol Pharmacol 1993; 44:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/15\">",
"      Takeuchi K, Yasuhiro T, Asada Y, Sugawa Y. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. Digestion 1998; 59:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/16\">",
"      Jim&eacute;nez D, Martin MJ, Pozo D, et al. Mechanisms involved in protection afforded by L-arginine in ibuprofen-induced gastric damage: role of nitric oxide and prostaglandins. Dig Dis Sci 2002; 47:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/17\">",
"      Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/18\">",
"      Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/19\">",
"      Horie-Sakata K, Shimada T, Hiraishi H, Terano A. Role of cyclooxygenase 2 in hepatocyte growth factor-mediated gastric epithelial restitution. J Clin Gastroenterol 1998; 27 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/20\">",
"      Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/21\">",
"      Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/22\">",
"      Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/23\">",
"      Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000; 279:G1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/24\">",
"      Fiorucci S, de Lima OM Jr, Mencarelli A, et al. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 2002; 123:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/25\">",
"      Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/26\">",
"      Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/27\">",
"      Kato K, Chen MC, Nguyen M, et al. Effects of growth factors and trefoil peptides on migration and replication in primary oxyntic cultures. Am J Physiol 1999; 276:G1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/28\">",
"      Babyatsky MW, deBeaumont M, Thim L, Podolsky DK. Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 1996; 110:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/29\">",
"      Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol 1994; 89:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/30\">",
"      Thillainayagam AV, Tabaqchali S, Warrington SJ, Farthing MJ. Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers. Dig Dis Sci 1994; 39:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/31\">",
"      Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 1992; 102:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/32\">",
"      Gubbins GP, Schubert TT, Attanasio F, et al. Helicobacter pylori seroprevalence in patients with rheumatoid arthritis: effect of nonsteroidal anti-inflammatory drugs and gold compounds. Am J Med 1992; 93:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/33\">",
"      Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/34\">",
"      Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/35\">",
"      Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/36\">",
"      Hawkey CJ. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 2000; 46:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/37\">",
"      Papatheodoridis GV, Papadelli D, Cholongitas E, et al. Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med 2004; 116:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/38\">",
"      Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/39\">",
"      Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006; 4:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/40\">",
"      Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/41\">",
"      Savage RL, Moller PW, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum 1993; 36:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/42\">",
"      Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/43\">",
"      Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/44\">",
"      Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/45\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/46\">",
"      Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/47\">",
"      Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/48\">",
"      Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/49\">",
"      Naschitz JE, Yeshurun D, Odeh M, et al. Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease. Am J Gastroenterol 1990; 85:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/50\">",
"      Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med 1987; 147:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/51\">",
"      Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/52\">",
"      Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/53\">",
"      Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/54\">",
"      Hern&aacute;ndez-D&iacute;az S, Rodr&iacute;guez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/55\">",
"      Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010; 32:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/56\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Lin KJ, Hern&aacute;ndez-D&iacute;az S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011; 123:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/57\">",
"      Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/58\">",
"      Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/59\">",
"      Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/60\">",
"      Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006; 119:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/61\">",
"      de Abajo FJ, Rodr&iacute;guez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/62\">",
"      Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/63\">",
"      de Abajo FJ, Garc&iacute;a-Rodr&iacute;guez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/64\">",
"      Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/65\">",
"      Fries JF, Williams CA, Ramey DR, Bloch DA. The relative toxicity of alternative therapies for rheumatoid arthritis: implications for the therapeutic progression. Semin Arthritis Rheum 1993; 23:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/66\">",
"      Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/37/6745/abstract/67\">",
"      Cryer B, Goldschmiedt M, Redfern JS, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology 1990; 99:1616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6745=[""].join("\n");
var outline_f6_37_6745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2782934\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTEMIC VERSUS TOPICAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE CENTRAL ROLE OF CYCLOOXYGENASE PRODUCTS (PROSTAGLANDINS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISMS OF GASTRODUODENAL PROTECTION BY ENDOGENOUS PGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ROLE OF NITRIC OXIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECTRUM OF GASTRODUODENAL MUCOSAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastric damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Duodenal damage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NSAID-INDUCED GASTRIC TOXICITY NOT MEDIATED THROUGH COX-1 INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ROLE OF HELICOBACTER PYLORI INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK OF GASTROINTESTINAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      American College of Gastroenterology recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RELATIONSHIP BETWEEN DYSPEPTIC SYMPTOMS AND GASTRODUODENAL MUCOSAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/8\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/8|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/8|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/16/39180\" title=\"table 1\">",
"      Selectivity of NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/4/25675\" title=\"table 2\">",
"      Patients at increased risk for NSAID gastrointestinal toxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26406?source=related_link\">",
"      NSAIDs: Adverse effects on the distal small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_37_6746="Intrinsic muscles of the hand";
var content_f6_37_6746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Intrinsic muscles of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 574px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagrams above depict the location of the muscles involved in finger and hand movement. Red represents a muscle's origin and blue a muscle's insertion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6746=[""].join("\n");
var outline_f6_37_6746=null;
var title_f6_37_6747="Minimal semen parameters recommended for sperm donors";
var content_f6_37_6747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimal semen parameters recommended for sperm donors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Volume",
"       </td>",
"       <td>",
"        &gt;2ml",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Sperm motility",
"       </td>",
"       <td>",
"        &gt;50% moving actively in a purposeful direction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Sperm concentration",
"       </td>",
"       <td>",
"        &gt;50 x 10(6) motile sperm/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Sperm morphology",
"       </td>",
"       <td>",
"        Normal range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Cryosurvival",
"       </td>",
"       <td>",
"        &gt;50 percent of initial motility",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: American Society of Reproductive Medicine. Fertil Steril 2002; 77:S15.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6747=[""].join("\n");
var outline_f6_37_6747=null;
var title_f6_37_6748="Stages of pediatric heart failure and therapy";
var content_f6_37_6748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stages of heart failure in infants and children and recommended therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Example",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        Patients with increased risk of developing HF, but with normal cardiac function and chamber size",
"       </td>",
"       <td>",
"        Exposure to cardiotoxic agents, family history of heritable cardiomyopathy, univentricular heart, congenitally corrected transposition of the great arteries",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        Patients with abnormal cardiac morphology or function, with no symptoms of HF, past or present",
"       </td>",
"       <td>",
"        Aortic insufficiency with LV enlargement, history of anthracycline exposure with decreased LV systolic function",
"       </td>",
"       <td>",
"        ACE inhibitors for patients with systemic ventricular dysfunction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        Patients with structural or functional heart disease, and past or current symptoms of HF",
"       </td>",
"       <td>",
"        Symptomatic cardiomyopathy or congenital heart defect with ventricular pump dysfunction",
"       </td>",
"       <td>",
"        ACE inhibitors, aldosterone antagonists and beta blockers for remodeling reversal; low dose digoxin and diuretics for symptom control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        Patients with end-stage HF requiring specialized interventions",
"       </td>",
"       <td>",
"        Marked symptoms at rest despite maximal medical therapy",
"       </td>",
"       <td>",
"        Intravenous diuretics and/or inotropes, positive pressure ventilation, mechanical circulatory support, heart transplantation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure; LV: left ventricular; ACE inhibitors: angiotensin converting enzyme inhibitors.",
"    </div>",
"    <div class=\"reference\">",
"     From: Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004; 23:1313. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6748=[""].join("\n");
var outline_f6_37_6748=null;
var title_f6_37_6749="IHC dermal spindle cell tumors";
var content_f6_37_6749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of immunohistochemical staining of dermatofibrosarcoma protuberans (DFSP) and other spindle cell dermal tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"8\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD34",
"       </td>",
"       <td class=\"subtitle1\">",
"        XIIIa",
"       </td>",
"       <td class=\"subtitle1\">",
"        S-100",
"       </td>",
"       <td class=\"subtitle1\">",
"        SMA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Desmin",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vimentin",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD44",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hyaluronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DFSP",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +/&ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatofibroma",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        +*",
"       </td>",
"       <td class=\"centered\">",
"        +/&ndash;*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodular fasciitis",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nerve sheath tumors",
"       </td>",
"       <td class=\"centered\">",
"        +/&ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrosarcoma",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant fibrous histiocytoma",
"       </td>",
"       <td class=\"centered\">",
"        +/&ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +/&ndash;",
"       </td>",
"       <td class=\"centered\">",
"        +",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SMA: smooth muscle actin; +: more than 80 percent of cases staining; &ndash;: less than 20 percent of cases staining; +/&ndash;: variable staining.",
"     <br/>",
"     * For dermatofibromas, cells stain intensely with CD44 while the stroma stains faintly for hyaluronate; DFSPs are strongly positive for hyaluronate while CD44 staining is diminished or absent.",
"    </div>",
"    <div class=\"reference\">",
"     Derived from: Haycox CL, et al. J Am Acad Dermatol 1997; 37:438 and Calikoglu E, et al. J Cutan Pathol 2003; 30:185.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6749=[""].join("\n");
var outline_f6_37_6749=null;
var title_f6_37_6750="Muscle innervation part C";
var content_f6_37_6750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Function and peripheral and segmental innervation of muscles: part C",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Plexus lumbalis: T12-L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Femoral nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion and outward rotation of hip",
"       </td>",
"       <td>",
"        Iliopsoas",
"       </td>",
"       <td>",
"        L1-L3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion and inward rotation of lower leg",
"       </td>",
"       <td>",
"        Sartorius",
"       </td>",
"       <td>",
"        L2-L3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of lower leg in knee joint",
"       </td>",
"       <td>",
"        Quadriceps femoris",
"       </td>",
"       <td>",
"        L2-L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Obturator nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"5\">",
"        Adduction of thigh",
"       </td>",
"       <td>",
"        Pectineus",
"       </td>",
"       <td>",
"        L2-L3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adductor longus",
"       </td>",
"       <td>",
"        L2-L3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adductor brevis",
"       </td>",
"       <td>",
"        L2-L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adductor magnus",
"       </td>",
"       <td>",
"        L3-L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gracilis",
"       </td>",
"       <td>",
"        L2-L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adduction and outward rotation of thigh",
"       </td>",
"       <td>",
"        Obturatorius externus",
"       </td>",
"       <td>",
"        L3-L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Plexus sacralis: L5-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Superior gluteal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Abduction and inward rotation of thigh",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Gluteus medius and minimus",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L4-L5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of upper leg in hip; abduction and inward rotation",
"       </td>",
"       <td>",
"        Tensor fasciae latae",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        L5-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Outward rotation of thigh and abduction",
"       </td>",
"       <td>",
"        Piriformis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Inferior gluteal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of thigh in hip",
"       </td>",
"       <td>",
"        Gluteus maximus",
"       </td>",
"       <td>",
"        L4-S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Outward rotation of thigh",
"       </td>",
"       <td>",
"        Obturatorius internus",
"       </td>",
"       <td>",
"        L5-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemelli",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quadratus",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Sciatic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Flexion of lower leg",
"       </td>",
"       <td>",
"        Biceps femoris",
"       </td>",
"       <td>",
"        L4-S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semitendinosus",
"       </td>",
"       <td>",
"        L4-S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semimembranosus",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Deep peroneal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dorsiflexion and supination of foot",
"       </td>",
"       <td>",
"        Tibialis anterior",
"       </td>",
"       <td>",
"        L4-L5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of toes and foot",
"       </td>",
"       <td>",
"        Extensor digitorum longus",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of toes II-V",
"       </td>",
"       <td>",
"        Extensor digitorum brevis",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of large toe",
"       </td>",
"       <td>",
"        Extensor hallucis longus",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of large toe",
"       </td>",
"       <td>",
"        Extensor hallucis brevis",
"       </td>",
"       <td>",
"        L4-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Superficial peronealnerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lifting and pronation of outer portion of foot",
"       </td>",
"       <td>",
"        Peronei",
"       </td>",
"       <td>",
"        L5-S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Tibial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plantar flexion of foot in supination",
"       </td>",
"       <td>",
"        <p>",
"         Gastrocnemius",
"        </p>",
"        <p>",
"         Triceps surae",
"        </p>",
"        <p>",
"         Soleus",
"        </p>",
"       </td>",
"       <td>",
"        L5-S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supination and plantar flexion of foot",
"       </td>",
"       <td>",
"        Tibialis posterior",
"       </td>",
"       <td>",
"        L4-L5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of distal phalanges of toes II-V (plantar flexion of foot in supination)",
"       </td>",
"       <td>",
"        Flexor digitorum longus",
"       </td>",
"       <td>",
"        L5-S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of distal phalanx of big toe",
"       </td>",
"       <td>",
"        Flexor hallucis longus",
"       </td>",
"       <td>",
"        L5-S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of middle phalanges of toes II-V",
"       </td>",
"       <td>",
"        Flexor digitorum brevis",
"       </td>",
"       <td>",
"        S1-S3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spreading, closing, and flexing of proximal phalanges of toes",
"       </td>",
"       <td>",
"        Plantaris pedis",
"       </td>",
"       <td>",
"        S1-S3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Pudendal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Closing of sphincters of bladder and rectum",
"       </td>",
"       <td>",
"        Perineal and sphincter musculature",
"       </td>",
"       <td>",
"        S2-S4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Duus, P. Topical Diagnosis in Neurology, 2nd ed. Thieme Medical Publishers, New York, 1989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6750=[""].join("\n");
var outline_f6_37_6750=null;
var title_f6_37_6751="Conduction block and slowing across the elbow";
var content_f6_37_6751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Motor nerve conduction study of ulnar innervated hypothenar muscles with conduction block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the typical findings for a motor nerve conduction study of the ulnar-innervated hypothenar muscles with conduction block and slowing across the elbow. The smaller response on the affected side is with stimulation above the elbow and reflects conduction block. In this case, the other two responses with stimulation at the wrist and below elbow are normal and the inset sensory response to the 5th digit is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_37_6751=[""].join("\n");
var outline_f6_37_6751=null;
